[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1199
1. Dellon ES, Shaheen NJ: Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? J Clin Oncol; 2005 Jul 10;23(20):4478-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival?
  • Despite the paucity of data supporting its use, screening upper endoscopy for patients with chronic gastroesophageal reflux disease symptoms to assess for Barrett's esophagus and esophageal adenocarcinoma has become a widely accepted practice.
  • We apply the principles of screening to Barrett's esophagus and esophageal adenocarcinoma.
  • The major fault with screening for Barrett's esophagus is that the at-risk population is too broadly characterized and that too many cancers occur outside of this risk pool.
  • Efforts may be better directed at further research identifying groups at risk for esophageal adenocarcinoma, developing more accurate and less-invasive methods of diagnosis, and discovering the underlying factors which continue to drive the increased incidence of this disease.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / complications. Mass Screening / economics


2. Bresalier R: Barrett's Metaplasia: defining the problem. Semin Oncol; 2005 Dec;32(6 Suppl 8):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's Metaplasia: defining the problem.
  • Concern over how best to manage individuals with Barrett's esophagus (BE) has grown because of the consistent rise in the incidence of esophageal adenocarcinoma.
  • Since the 1970s, the rate of increase in incidence of esophageal adenocarcinoma has been greater than that for any other cancer in the US population.
  • Much remains to be learned about BE and its association with adenocarcinoma before effective surveillance or management strategies can be defined and implemented.
  • In this article, the relationship between BE and gastroesophageal reflux disease, risk for adenocarcinoma, and prospects for molecular diagnosis are discussed.
  • [MeSH-major] Barrett Esophagus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360008.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


3. Arra A, Nieva NB, Rey N, Fernández AO: [Cytokeratin 7 and 20 in Barrett's esophagus]. Rev Fac Cien Med Univ Nac Cordoba; 2005;62(3):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytokeratin 7 and 20 in Barrett's esophagus].
  • [Transliterated title] Citoqueratinas 7 y 20 en el esófago de Barrett.
  • Barrett's esophagus (BE) has been identified as the most important risk factor for adenocarcinoma of the distal esophagus.
  • Intestinal metaplasia may also develop in gastric mucosa (IMG) at the gastroesophageal junction.
  • Barrett's CK7/20 pattern was characterized by superficial and deep CK7 reactivity and only superficial CK 20 staining in the intestinalized mucosa.
  • 67% of the biopsy specimens from patients with endoscopic SSBE showed Barrett's CK7/20 pattern, and the remaining 33% specimens showed the IMG staining pattern.
  • [MeSH-major] Barrett Esophagus / pathology. Esophagogastric Junction / pathology. Keratin-20 / analysis. Keratin-7 / analysis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972735.001).
  • [ISSN] 0014-6722
  • [Journal-full-title] Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)
  • [ISO-abbreviation] Rev Fac Cien Med Univ Nac Cordoba
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


Advertisement
4. Zehetner J, DeMeester SR: Treatment of Barrett's esophagus with high-grade dysplasia and intramucosal adenocarcinoma. Expert Rev Gastroenterol Hepatol; 2009 Oct;3(5):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Barrett's esophagus with high-grade dysplasia and intramucosal adenocarcinoma.
  • High-grade dysplasia and intramucosal adenocarcinoma are premalignant and malignant lesions of the esophagus.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Esophagoscopy. Esophagus / surgery. Precancerous Conditions / surgery

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817671.001).
  • [ISSN] 1747-4132
  • [Journal-full-title] Expert review of gastroenterology & hepatology
  • [ISO-abbreviation] Expert Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  •  go-up   go-down


5. Kim CW, Lee BI, Kim BW, Kim JI, Park SH, Kim JK, Han SW, Jung IS, Sun HS, Lee AW, Lee KY: [Immunohistochemical expression of the p53 and Ki-67 proteins in Barrett's esophagus in Korea]. Korean J Gastroenterol; 2005 Sep;46(3):189-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of the p53 and Ki-67 proteins in Barrett's esophagus in Korea].
  • BACKGROUND/AIMS: Barrett's esophagus is a premalignant lesion of the esophagus in which normal squamous epithelium is replaced by intestinalized columnar epithelium.
  • In Korea, adenocarcinoma associated with Barrett's esophagus is rare compared with that of Western country.
  • The purpose of this study was to investigate the immunohistochemical expression of p53 and Ki-67 in Barrett's esophagus which had predictive value for cancer risk in Korea.
  • METHODS: Ninety five patients (43 male and 52 female, median age 44, range 21-75) who have been suspected to have Barrett's esophagus by endoscopic assessment were enrolled in this study.
  • 56.4% (31/55) of Barrett's esophagus showed sulfomucin positive colonic metaplasia.
  • The p53 expression was observed in 10.9% (6/55) of the patients of Barrett's esophagus and all of them showed colonic metaplasia.
  • CONCLUSIONS: In Korea, 10.9% of Barrett's esophagus had p53 mutation and moreover all of them had colonic metaplasia.
  • Consequently, we expect that these patients have high risk of developing dysplasia and adenocarcinoma and need careful follow-up.
  • [MeSH-major] Barrett Esophagus / metabolism. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / genetics. Adult. Aged. Esophageal Neoplasms / etiology. Esophageal Neoplasms / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179838.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Geddert H, Kiel S, Zotz RB, Zhang J, Willers R, Gabbert HE, Sarbia M: Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol; 2005 Dec;131(12):803-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using PCR based restriction fragment length polymorphism and single strand conformational polymorphism, we determined single nucleotide exchanges in the p16 and cyclin D1 genes among 56 esophageal adenocarcinomas (ADC) arising in Barrett's esophagus, 95 cardiac gastric ADC, and in 191 distal gastric ADC.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclin D1 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Esophageal Neoplasms / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine. Barrett Esophagus / complications. Cardia. Case-Control Studies. Cysteine. DNA, Neoplasm / analysis. Female. Gene Frequency. Glycine. Homozygote. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Polymorphism, Single Nucleotide. Polymorphism, Single-Stranded Conformational

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1195-9 [11470749.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):176 [12582032.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):404-14 [10862049.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):640-5 [12101111.001]
  • [Cites] Oncogene. 1995 Sep 7;11(5):1005-11 [7675441.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):476-86 [15297940.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1499-503 [12807740.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):98-103 [12532425.001]
  • [Cites] Int J Cancer. 2004 Mar;109(1):138-43 [14735480.001]
  • [Cites] Int J Cancer. 1998 Jan 19;75(2):193-8 [9462707.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Urology. 2004 Jul;64(1):74-8 [15245939.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1007-10 [11490786.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):281-4 [12673692.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 14;1378(2):F115-77 [9823374.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1405 [12151361.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2843-8 [14657069.001]
  • (PMID = 16163549.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 136601-57-5 / Cyclin D1; K848JZ4886 / Cysteine; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
  •  go-up   go-down


7. Morganstern B, Anandasabapathy S: GERD and Barrett's esophagus: diagnostic and management strategies in the geriatric population. Geriatrics; 2009 Jul;64(7):9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GERD and Barrett's esophagus: diagnostic and management strategies in the geriatric population.
  • Chronic gastroesophageal reflux disease (GERD) is a risk factor for the development of Barrett's esophagus, the predominant precursor to esophageal adenocarcinoma.
  • It is important for the primary care physician to identify those at greatest risk of developing Barrett's esophagus for referral for appropriate endoscopic screening.
  • The primary care physician must maintain a high index of suspicion and refer anyone who may potentially be at risk of Barrett's esophagus to a gastroenterologist.
  • Once a diagnosis of Barrett's esophagus is made, appropriate endoscopic surveillance is indicated.
  • [MeSH-major] Adenocarcinoma / prevention & control. Barrett Esophagus / etiology. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / diagnosis. Gastroesophageal Reflux / drug therapy. Precancerous Conditions / etiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586085.001).
  • [ISSN] 1936-5764
  • [Journal-full-title] Geriatrics
  • [ISO-abbreviation] Geriatrics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


8. van Lanschot JJ: Oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol; 2006;20(5):801-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Esophageal Neoplasms
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / diagnosis. Barrett Esophagus / epidemiology. Barrett Esophagus / pathology. Barrett Esophagus / therapy. Humans. Neoplasm Staging. Risk Factors. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997161.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Hahn HP, Shahsafaei A, Odze RD: Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett esophagus. Am J Surg Pathol; 2008 Oct;32(10):1454-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett esophagus.
  • A well-known type of mesenchymal/epithelial interaction occurs in Barrett esophagus (BE) characterized by the formation of a new, superficially located, muscularis mucosae (MM), which results in the division of the lamina propria (LP) into a superficial and deep compartment.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Endothelium, Lymphatic / pathology. Endothelium, Vascular / pathology. Esophageal Neoplasms / pathology. Esophagus / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685488.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD31; 0 / monoclonal antibody D2-40
  •  go-up   go-down


10. Pedrosa MC: The hunt for dysplasia in Barrett's esophagus. Gastrointest Endosc; 2009 Dec;70(6):1079-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The hunt for dysplasia in Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy. Endoscopy, Gastrointestinal. Esophageal Neoplasms / pathology. Humans

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gastrointest Endosc. 2009 Dec;70(6):1072-8.e1 [19595312.001]
  • (PMID = 19962499.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


11. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY: Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol; 2005 Aug;124(2):282-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.
  • Overexpression of decoy receptor (DcR) 3 protein, a recently discovered member of the tumor necrosis factor receptor superfamily, was examined in 40 esophagogastrectomy specimens containing areas of Barrett esophagus (n = 27), low-grade dysplasia (n = 27), high-grade dysplasia or carcinoma in situ (n = 22), and esophageal adenocarcinoma (EAC; n = 28) with immunohistochemical analysis.
  • The results revealed significantly more overexpression of DcR3 in high-grade dysplasia or carcinoma in situ and EAC than in benign esophageal mucosa (both P < .0001), Barrett esophagus (both P < .001), and low-grade dysplasia (P < .01 and P = .033, respectively).
  • Low-grade dysplasia also showed significant overexpression of DcR3 compared with benign esophagus (P < .05) but not with Barrett esophagus (P > .05).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Esophageal Neoplasms / metabolism. Membrane Glycoproteins / biosynthesis. Precancerous Conditions / metabolism. Receptors, Cell Surface / biosynthesis. Receptors, Tumor Necrosis Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040301.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


12. Sabo E, Meitner PA, Tavares R, Corless CL, Lauwers GY, Moss SF, Resnick MB: Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res; 2008 Oct 15;14(20):6440-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue.
  • Immunohistochemistry confirmed increased protein expression for topoisomerase IIalpha, S100A9, and lipocalin-2 and decreased expression of TFF1 across the spectrum of BE-associated dysplasia from NDBE through adenocarcinoma.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] J Pathol. 2006 Jan;208(1):100-7 [16278815.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):383-92 [11487270.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):167-74 [11815973.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3493-7 [12067993.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):660-8 [12152167.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1540-1 [12424128.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3233-42 [12626582.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):300-4 [12704661.001]
  • [Cites] J Histochem Cytochem. 2003 May;51(5):675-85 [12704215.001]
  • [Cites] Ann Thorac Surg. 2004 Mar;77(3):1008-15 [14992916.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]
  • [Cites] Nutr Cancer. 2004;48(1):6-14 [15203372.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2571-6 [8428933.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):119-29 [8514029.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3379-82 [8012954.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):613-34 [9309409.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1127-33 [10070973.001]
  • [Cites] Mod Pathol. 1999 Apr;12(4):356-61 [10229499.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):65-72 [15358636.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):390-9 [15725809.001]
  • [Cites] Cancer Sci. 2006 May;97(5):411-9 [16630140.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):925-33 [16952561.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1304-15 [16949933.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1029-38 [17021130.001]
  • [Cites] Gut. 2006 Dec;55(12):1717-24 [16641130.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] J Mol Diagn. 2007 Feb;9(1):70-9 [17251338.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):555-61 [17412867.001]
  • [Cites] Scand J Gastroenterol. 2007 Aug;42(8):902-10 [17613918.001]
  • [Cites] Eur J Cancer. 2007 Aug;43(12):1869-76 [17604154.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(2):194-7 [17768422.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2478-85 [15814623.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):407-16 [15967118.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5390-5 [16061852.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7127-36 [16103062.001]
  • [Cites] Biochem J. 2005 Oct 15;391(Pt 2):441-8 [16060857.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Surgery. 2005 Oct;138(4):788-94 [16269310.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):5393-8 [10697567.001]
  • (PMID = 18927283.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017695; United States / NCRR NIH HHS / RR / RR017695-057272; United States / NCRR NIH HHS / RR / P20 RR017695-057272; United States / NCRR NIH HHS / RR / P20 RR17695
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS72917; NLM/ PMC2701739
  •  go-up   go-down


13. Messmann H, Ell C, Fein M, Kiesslich R, Ortner M, Porschen R, Stolte M: [Topic Complex VI: Barrett esophagus]. Z Gastroenterol; 2005 Feb;43(2):184-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topic Complex VI: Barrett esophagus].
  • [Transliterated title] Themenkomplex VI: Barrett-Osophagus.
  • [MeSH-major] Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Precancerous Conditions / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Biopsy. Cell Transformation, Neoplastic / pathology. Endosonography. Esophagus / pathology. Gastroscopy. Humans. Metaplasia. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15700212.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Consensus Development Conference; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 97
  •  go-up   go-down


14. Bergman JJ: Radiofrequency ablation--great for some or justified for many? N Engl J Med; 2009 May 28;360(22):2353-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Barrett Esophagus / surgery. Catheter Ablation. Esophagus / pathology
  • [MeSH-minor] Adenocarcinoma / prevention & control. Disease Progression. Esophageal Neoplasms / prevention & control. Humans. Metaplasia / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • (PMID = 19474433.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


15. Khushalani N: Cancer of the esophagus and stomach. Mayo Clin Proc; 2008 Jun;83(6):712-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Barrett esophagus has been well characterized, the exact pathway to developing frank malignancy remains undefined.
  • Studies in the English language were identified searching PubMed (January 1, 1980, through February 29, 2008) using the terms esophagus, gastric, carcinoma, adenocarcinoma, squamous cell, radiation, chemotherapy, surgery, esophagectomy, and targeted therapy.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533089.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 136
  •  go-up   go-down


16. Falk GW: The future of endoscopic treatment of early Barrett neoplasia: the endoscopist's view. Endoscopy; 2008 Dec;40(12):1041-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The future of endoscopic treatment of early Barrett neoplasia: the endoscopist's view.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Esophagoscopy / trends. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065489.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 52
  •  go-up   go-down


17. Helm J, Enkemann SA, Coppola D, Barthel JS, Kelley ST, Yeatman TJ: Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin Cancer Res; 2005 Apr 1;11(7):2478-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
  • PURPOSE: Adenocarcinoma arises in Barrett's esophagus by progression from metaplasia to cancer through grades of dysplasia.
  • Our aim in this exploratory study was to characterize the broad changes in gene expression that underlie this histologic progression to cancer and assess the potential for using these gene expression changes as a marker predictive of malignant progression in Barrett's epithelium.
  • EXPERIMENTAL DESIGN: Microarray analysis was used to obtain individual gene expression profiles from endoscopic biopsies of nine esophageal adenocarcinomas and the Barrett's epithelia from which three of the cancers had arisen.
  • Pooled samples from the Barrett's epithelia of six patients without cancer or dysplasia served as a reference.
  • RESULTS: Barrett's epithelia from which cancer had arisen differed from the reference Barrett's epithelia primarily by underexpression of genes, many of which function in governing cell differentiation.
  • These changes in gene expression were found even in those specimens of Barrett's epithelia from which cancer had arisen that lacked dysplasia.
  • Each cancer differed from the Barrett's epithelium from which it had arisen primarily by an overexpression of genes, many of which were associated with tissue remodeling and invasiveness.
  • Cancers without identifiable Barrett's epithelium differed from cancers that had arisen from a Barrett's epithelium by having an even greater number of these overexpressed genes.
  • CONCLUSIONS: Histologic progression from Barrett's epithelium to cancer is associated with a gradient of increasing changes in gene expression characterized by an early loss of gene function governing differentiation that begins before histologic change; gain in function of genes related to remodeling and invasiveness follows later.
  • This correlation of histologic progression with increasing changes in gene expression suggests that gene expression changes in biopsies taken from Barrett's epithelium potentially could serve as a marker for neoplastic progression that could be used to predict risk for developing cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Gene Expression Profiling

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814623.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24-CA85429-04; United States / NCI NIH HHS / CA / R01-CA098522-01; United States / NCI NIH HHS / CA / RZ1-CA101355-01-A1; United States / NCI NIH HHS / CA / U01-CA85052-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Wang KK: Esophageal adenocarcinoma. Clin Gastroenterol Hepatol; 2006 Oct;4(10):1221-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Feb;4(2):173-8 [16469677.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):252-7 [15017665.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1468-70 [15887128.001]
  • (PMID = 16979951.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA097048-01; United States / NCI NIH HHS / CA / R01CA097048; United States / NCI NIH HHS / CA / R01 CA111603; United States / NCI NIH HHS / CA / R01 CA111603-01A1; United States / NCI NIH HHS / CA / R01CA111603-01A1; United States / NCI NIH HHS / CA / R01 CA097048
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS86233; NLM/ PMC2646411
  •  go-up   go-down


19. Michor F, Polyak K: The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila); 2010 Nov;3(11):1361-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this issue of the journal (beginning on page 1388), Merlo et al. report their use of molecular data from 239 patients with Barrett's esophagus to evaluate the propensity of major diversity indices for predicting progression to esophageal adenocarcinoma.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Cell Stem Cell. 2010 Feb 5;6(2):141-52 [20144787.001]
  • [Cites] J Clin Invest. 2010 Feb;120(2):636-44 [20101094.001]
  • [Cites] Cancer Prev Res (Phila). 2010 May;3(5):579-87 [20424132.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97 [20947487.001]
  • [Cites] Science. 2000 Sep 8;289(5485):1754-7 [10976069.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Genetics. 2003 Apr;163(4):1527-32 [12702695.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6212-20 [14559806.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6635-42 [14583456.001]
  • [Cites] J Theor Biol. 2003 Dec 7;225(3):377-82 [14604590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14966-9 [14657359.001]
  • [Cites] Bull Math Biol. 2004 Jul;66(4):663-87 [15210312.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Cancer Res. 1978 Sep;38(9):2651-60 [354778.001]
  • [Cites] Cancer Treat Rep. 1983 Oct;67(10):923-31 [6627236.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2259-65 [6372991.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Semin Cell Dev Biol. 2005 Aug-Oct;16(4-5):554-63 [16144692.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):899-904 [16327766.001]
  • [Cites] Blood. 2010 Mar 11;115(10):1976-84 [20053758.001]
  • [Cites] Curr Pharm Des. 2006;12(3):261-71 [16454743.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1891-5; discussion 1890 [16488984.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] J Theor Biol. 2006 Jun 21;240(4):521-30 [16343545.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2017-27 [17071472.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):924-35 [17109012.001]
  • [Cites] Cell Cycle. 2007 Feb 15;6(4):461-6 [17329969.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):204-13 [16787749.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2695-706 [17057735.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2332-8 [17786053.001]
  • [Cites] PLoS Comput Biol. 2007 Dec;3(12):e250 [18085819.001]
  • [CommentOn] Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97 [20947487.001]
  • (PMID = 20959519.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA143798; United States / NCI NIH HHS / CA / U54CA143798
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS240068; NLM/ PMC3633425
  •  go-up   go-down


20. Tadiparthi R, Bansal A, Sharma P: What's new in columnar lined esophagus (Barrett's metaplasia)? Curr Opin Gastroenterol; 2008 Jul;24(4):516-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What's new in columnar lined esophagus (Barrett's metaplasia)?
  • PURPOSE OF REVIEW: The rising incidence of esophageal adenocarcinoma in the Western world has led to continued interest in its precursor lesion, Barrett's esophagus.
  • This review endeavors to summarize the recent advances in our understanding of Barrett's esophagus with an emphasis on novel imaging techniques and endoscopic therapies.
  • RECENT FINDINGS: There are indications that ethnic minorities such as blacks and Hispanics are at considerably lower risk for Barrett's esophagus (<2%) compared with whites.
  • Central obesity rather than BMI could be a more important determinant of Barrett's metaplasia and neoplasia.
  • SUMMARY: A better appreciation of risk factors that lead to Barrett's esophagus and its neoplastic progression may help in formulating early intervention strategies.
  • The emergence of novel imaging modalities for early and accurate detection of dysplasia, combined with new therapies, may have a substantial impact in improving outcomes among Barrett's esophagus patients.
  • [MeSH-major] Barrett Esophagus / pathology. Barrett Esophagus / therapy. Population Surveillance
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Esophageal Neoplasms / etiology. Esophageal Neoplasms / pathology. Esophageal Neoplasms / prevention & control. Humans. Metaplasia / pathology. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622169.001).
  • [ISSN] 1531-7056
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


21. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ: Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut; 2010 Aug;59(8):1030-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study.
  • BACKGROUND: Reported incidence rates of oesophageal adenocarcinoma (OAC) in Barrett's oesophagus (BO) vary widely.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20639249.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


22. Bustamante M, Bernet L: [p53 Protein expression from mild dysplasia to adenocarcinoma in a patient with Barrett's esophagus: an immunohistochemical study]. Rev Esp Enferm Dig; 2006 Aug;98(8):631-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [p53 Protein expression from mild dysplasia to adenocarcinoma in a patient with Barrett's esophagus: an immunohistochemical study].
  • [Transliterated title] Expresión de la proteína p53 desde displasia leve hasta adenocarcinoma en un paciente con esófago de Barrett: un estudio con inmunohistoquimia.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Esophageal Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17049004.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Wang DH, Clemons NJ, Miyashita T, Dupuy AJ, Zhang W, Szczepny A, Corcoran-Schwartz IM, Wilburn DL, Montgomery EA, Wang JS, Jenkins NA, Copeland NA, Harmon JW, Phillips WA, Watkins DN: Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology; 2010 May;138(5):1810-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
  • BACKGROUND & AIMS: The molecular mechanism underlying epithelial metaplasia in Barrett's esophagus remains unknown.
  • Recognizing that Hedgehog signaling is required for early esophageal development, we sought to determine if the Hedgehog pathway is reactivated in Barrett's esophagus, and if genes downstream of the pathway could promote columnar differentiation of esophageal epithelium.
  • Human esophageal squamous epithelial (HET-1A) and adenocarcinoma (OE33) cells were subjected to acid treatment and used in transfection experiments.
  • RESULTS: Marked up-regulation of Hedgehog ligand expression, which can be induced by acid or bile exposure, occurs frequently in Barrett's epithelium and is associated with stromal expression of the Hedgehog target genes PTCH1 and BMP4.
  • BMP4 signaling induces expression of SOX9, an intestinal crypt transcription factor, which is highly expressed in Barrett's epithelium.
  • We further show that expression of Deleted in Malignant Brain Tumors 1, the human homologue of the columnar cell factor Hensin, occurs in Barrett's epithelium and is induced by SOX9.
  • CONCLUSIONS: Epithelial Hedgehog ligand expression may contribute to the initiation of Barrett's esophagus through induction of stromal BMP4, which triggers reprogramming of esophageal epithelium in favor of a columnar phenotype.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Development. 1998 Aug;125(15):2791-801 [9655802.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):54-7 [9731531.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):58-61 [9731532.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):211-3 [9888459.001]
  • [Cites] J Cell Biol. 1999 Mar 8;144(5):1057-67 [10085301.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 2):F277-89 [10444583.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Dev Biol. 2005 Mar 15;279(2):481-90 [15733673.001]
  • [Cites] Dev Biol. 2005 Aug 1;284(1):157-70 [15992795.001]
  • [Cites] Curr Biol. 2005 Aug 9;15(15):1340-51 [16085486.001]
  • [Cites] Pathol Res Pract. 2005;201(8-9):573-7 [16259110.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1696-710 [16285967.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] J Surg Res. 2006 Jul;134(1):1-9 [16488438.001]
  • [Cites] Differentiation. 2006 Sep;74(7):422-37 [16916379.001]
  • [Cites] Nucleic Acids Res. 2007;35(4):1178-86 [17264118.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2412-21 [17570215.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):539-46 [17681175.001]
  • [Cites] J Cell Biol. 2007 Aug 13;178(4):635-48 [17698607.001]
  • [Cites] Scand J Gastroenterol. 2008;43(10):1158-68 [18609138.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):887-96 [17678919.001]
  • [Cites] Development. 2000 May;127(9):1971-80 [10751185.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):322-37 [11224619.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):317-28 [11487541.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):307-18 [11718263.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8880-6 [11751412.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1829-37 [14691301.001]
  • [Cites] J Cell Biol. 2004 Jul 5;166(1):37-47 [15240568.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Development. 2004 Aug;131(15):3795-804 [15240557.001]
  • [Cites] J Bone Miner Res. 2004 Oct;19(10):1678-88 [15355563.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):402 [15385990.001]
  • [Cites] J Cell Biol. 2004 Sep 27;166(7):1093-102 [15452149.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Br J Surg. 1988 Feb;75(2):113-5 [3349294.001]
  • [Cites] Am J Gastroenterol. 1988 Jun;83(6):629-32 [3376916.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1053-61 [8137422.001]
  • [Cites] Development. 1995 Oct;121(10):3163-74 [7588051.001]
  • [Cites] Anat Rec. 1996 Mar;244(3):327-43 [8742698.001]
  • [Cites] J Clin Invest. 1996 Nov 15;98(10):2324-31 [8941650.001]
  • [Cites] J Cell Sci. 1997 Mar;110 ( Pt 5):663-71 [9092948.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):49-61 [9720756.001]
  • (PMID = 20138038.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA123945-03; United States / NCI NIH HHS / CA / F32 CA123945-03; United States / NCI NIH HHS / CA / F32 CA123945-02; United States / NCI NIH HHS / CA / F32 CA123945-01; United States / NIDDK NIH HHS / DK / 1K23DK068149; United States / NIDDK NIH HHS / DK / K23 DK068149; United States / NCI NIH HHS / CA / CA123945-01; United States / NCI NIH HHS / CA / F32CA-123945; United States / NCI NIH HHS / CA / F32 CA123945; United States / NCI NIH HHS / CA / CA123945-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / Bmp4 protein, mouse; 0 / Bone Morphogenetic Protein 4; 0 / DMBT1 protein, human; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human; 0 / Shh protein, mouse; 0 / Sox9 protein, mouse; 0 / patched receptors; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ NIHMS176618; NLM/ PMC3422577
  •  go-up   go-down


24. Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea CM, Javle MM: Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology; 2007;73(5-6):281-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophageal adenocarcinoma (EAC) is one of the fastest growing malignancies in the US.
  • Studies conducted by us and others have shown that the overexpression of EGFR family signaling intermediates is common in Barrett's esophagus and EAC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Esophageal Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Barrett Esophagus / drug therapy. Barrett Esophagus / epidemiology. Erlotinib Hydrochloride. Humans. Incidence. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use. Survival Analysis

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18477853.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / matuzumab; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Number-of-references] 57
  •  go-up   go-down


25. Ooi A, Zen Y, Ninomiya I, Tajiri R, Suzuki S, Kobayashi H, Imoto I, Dobashi Y: Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. Pathol Int; 2010 Jun;60(6):466-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus.
  • We examined 11 cases of carcinoma arising from Barrett's esophagus consisting of two adenocarcinomas in situ (ACIS), two intramucosal adenocarcinomas, and seven overt invasive adenocarcinomas.
  • In all cases of ACIS and the intramucosal adenocarcinomas, almost all cancer cells overexpressed p53, however the populations overexpressing ERBB2 and EGFR varied in different cases: in one ACIS, ERBB2 was coexpressed in all the cancer cells, in the other ACIS and one intramucosal adenocarcinoma, ERBB2 was overexpressed in about 50% and only 10% of the p53-positive cells respectively.
  • EGFR was co-expressed in 20% in the other intramucosal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Carcinoma in Situ / genetics. Gene Amplification. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics


26. Mardini HE: Preventing dysplasia in Barrett's esophagus: are proton pump inhibitors the answer? Am J Gastroenterol; 2005 Apr;100(4):978-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventing dysplasia in Barrett's esophagus: are proton pump inhibitors the answer?
  • [MeSH-major] Adenocarcinoma / prevention & control. Barrett Esophagus / drug therapy. Cell Transformation, Neoplastic / drug effects. Esophageal Neoplasms / prevention & control. Precancerous Conditions / prevention & control. Proton Pump Inhibitors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • (PMID = 15784046.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


27. Kadioglu E, Sardas S, Ergun M, Unal S, Karakaya AE: The role of oxidative DNA damage, DNA repair, GSTM1, SOD2 and OGG1 polymorphisms in individual susceptibility to Barrett's esophagus. Toxicol Ind Health; 2010 Mar;26(2):67-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of oxidative DNA damage, DNA repair, GSTM1, SOD2 and OGG1 polymorphisms in individual susceptibility to Barrett's esophagus.
  • Determination of the genetic alterations, which play a role in the etiology of Barrett's esophagus (BE), could help identify high-risk individuals for esophageal adenocarcinoma (EA).
  • [MeSH-major] Barrett Esophagus / enzymology. Barrett Esophagus / genetics. DNA Damage / physiology. DNA Glycosylases / genetics. Glutathione Transferase / genetics. Superoxide Dismutase / genetics

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20056743.001).
  • [ISSN] 1477-0393
  • [Journal-full-title] Toxicology and industrial health
  • [ISO-abbreviation] Toxicol Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; BBX060AN9V / Hydrogen Peroxide; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; GAN16C9B8O / Glutathione
  •  go-up   go-down


28. Lao-Sirieix P, Boussioutas A, Kadri SR, O'Donovan M, Debiram I, Das M, Harihar L, Fitzgerald RC: Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut; 2009 Nov;58(11):1451-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic.
  • BACKGROUND AND AIMS: Barrett's oesophagus predisposes to oesophageal adenocarcinoma but the majority of patients are undiagnosed.
  • However, due to the mixed cell population retrieved by the capsule sponge, biomarkers specific for Barrett's oesophagus are required.
  • METHODS: Three publically available microarray datasets were used to identify putative biomarkers present in Barrett's oesophagus but absent from normal oesophagus and gastric mucosa.
  • Validation was performed by qPCR (n = 10 each of normal oesophagus, Barrett's oesophagus, gastric mucosa) and immunohistochemistry (normal oesophagus, n = 20; Barrett's oesophagus, n = 21; gastric mucosa, n = 24; duodenum, n = 18).
  • The biomarker was then prospectively evaluated on capsule sponge specimens from 47 patients with Barrett's oesophagus and 99 healthy controls.
  • RESULTS: 2/14 genes identified, dopa decarboxylase (DDC) and Trefoil factor 3 (TFF3), were confirmed by qPCR to be upregulated in Barrett's oesophagus compared to normal oesophagus (p<0.01) and gastric mucosa (p<0.01 and p<0.05, respectively).
  • Immunohistochemistry confirmed that DDC protein expression was restricted to Barrett's oesophagus but was confined to <1% of the cells within the crypt compartment.
  • TFF3 protein was expressed to high levels at the luminal surface of Barrett's oesophagus compared to absent expression in normal oesophagus and gastric mucosa (p<0.001).
  • Using the capsule sponge 36/46 patients with Barrett's oesophagus (one inadequate sample) and 6/96 controls were positive for TFF3 giving a sensitivity of 78% and a specificity of 94%.
  • CONCLUSIONS: TFF3 is a promising marker for Barrett's oesophagus screening since it is expressed at the luminal surface of Barrett's oesophagus but not in adjacent tissue types and may be applied to a non-endoscopic screening device.
  • [MeSH-major] Barrett Esophagus / genetics. Biomarkers, Tumor / metabolism. Dopa Decarboxylase / metabolism. Esophageal Neoplasms / genetics. Peptides / metabolism. Precancerous Conditions / genetics
  • [MeSH-minor] Aged. Female. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Protein Array Analysis. Reference Values. Trefoil Factor-3. Up-Regulation


29. Colleypriest BJ, Farrant JM, Slack JM, Tosh D: The role of Cdx2 in Barrett's metaplasia. Biochem Soc Trans; 2010 Apr;38(2):364-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of Cdx2 in Barrett's metaplasia.
  • Barrett's metaplasia describes the development of a columnar/intestinal phenotype in the squamous oesophageal epithelium and is the major risk factor for oesophageal adenocarcinoma.
  • The homoeotic transcription factor Cdx2 (Caudal-type homeobox 2) has been implicated as a master switch gene for intestine and therefore for Barrett's metaplasia.
  • In the present paper, we review the evidence for the role of Cdx2 in the development of Barrett's metaplasia.
  • [MeSH-major] Barrett Esophagus / genetics. Esophagus / pathology. Homeodomain Proteins / physiology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Animals. CDX2 Transcription Factor. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Humans. Metaplasia / genetics. Models, Biological

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298184.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300415; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  • [Number-of-references] 72
  •  go-up   go-down


30. Watson TJ: Endoscopic resection for Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma. Semin Thorac Cardiovasc Surg; 2008;20(4):310-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection for Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma.
  • The incidence of esophageal adenocarcinoma continues to rise in the United States and Western Europe.
  • With the introduction of screening and surveillance programs for Barrett's esophagus, the precursor of esophageal adenocarcinoma, early esophageal neoplasia is being recognized on an increasing basis.
  • Esophagectomy is the current standard of care for patients found to have Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma and determined to be at suitable risk for surgical intervention.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Esophagoscopy / methods. Precancerous Conditions / surgery

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251170.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


31. Bergman JJ: The endoscopic diagnosis and staging of oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol; 2006;20(5):843-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endoscopic diagnosis and staging of oesophageal adenocarcinoma.
  • The endoscopic evaluation of patients with oesophageal adenocarcinoma does not only serve the purpose of diagnosing the lesion and obtaining biopsies for histological evaluation: a systematic description of advanced lesions is also required to guide further therapeutic decisions.
  • New endoscopic imaging modalities hold the promise of better endoscopic detection of early cancer and its precursor lesions in Barrett's oesophagus.
  • Endoscopic ultrasonography (EUS) is superior to any other imaging modality in the assessment of local tumour infiltration of oesophageal adenocarcinoma and locoregional lymph nodes status.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagoscopy
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Barrett Esophagus / therapy. Biopsy, Fine-Needle. Endosonography. Humans. Neoadjuvant Therapy. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997165.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


32. Bird-Lieberman EL, Fitzgerald RC: Barrett's esophagus. Gastroenterol Clin North Am; 2008 Dec;37(4):921-42, x
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • Barrett's esophagus is an important step in the pathway to esophageal adenocarcinoma.
  • Since most patients with Barrett's esophagus are undiagnosed and patients present with advanced adenocarcinoma de novo, prognosis for this disease remains poor.
  • To identify those people with Barrett's esophagus who are at particular risk many new technologies are being developed.
  • In association with these advances in risk stratification, progress is being made in the endoscopic treatment of Barrett's.
  • [MeSH-major] Barrett Esophagus

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028325.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 131
  •  go-up   go-down


33. Tokar JL, Haluszka O, Weinberg DS: Endoscopic therapy of dysplasia and early-stage cancers of the esophagus. Semin Radiat Oncol; 2007 Jan;17(1):10-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PDT has been reported to eradicate high-grade dysplasia (HGD) and early Barrett's cancers at rates ranging from 75% to 100% and 17% to 100%, respectively, and a recent randomized controlled trial confirmed that PDT may prevent progression of HGD to cancer.
  • Complete remission rates greater than 90% have also been reported with EMR and other mucosa-ablating interventions, although recurrence rates necessitate close endoscopic surveillance and retreatment in some patients.
  • [MeSH-minor] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Catheter Ablation. Esophagus / pathology. Humans. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185193.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 115
  •  go-up   go-down


34. Hermann B, Li Y, Ray MB, Wo JM, Martin RC 2nd: Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus. Arch Surg; 2005 Dec;140(12):1204-9; discussion 1209
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.
  • HYPOTHESIS: The down-regulation of manganese superoxide dismutase (MnSOD) expression plays a role in the progression of Barrett esophagus (BE).
  • DESIGN: An evaluation of 92 esophageal samples, including 17 patients with normal esophagus, 22 with intestinal metaplasia, 22 with indefinite/low-grade dysplasia, 16 with high-grade dysplasia (HGD), and 15 with esophageal adenocarcinoma were evaluated for MnSOD expression.
  • We evaluated MnSOD expression using immunohistochemistry and graded it separately on a 2-category ordinal scale in relation to the mucosa and submucosa that ranged from 0 (no staining) to 3 (strong staining).
  • The total grading score of MnSOD immunoreactivity was the addition of mucosa and submucosa intensity, from 0 (no immunoreactivity in any of the anatomic sites) to a maximum score of 6 (strong staining reaction in both of the histoanatomic sites).
  • SETTING: Study subjects were recruited from the Barrett's Esophageal Registry at the University of Louisville, Louisville, KY.
  • The expression of MnSOD was found to be significantly reduced in samples with specialized intestinal metaplasia (mean score, 1.8), low-grade dysplasia (mean, 2.2), high-grade dysplasia (mean, 2.4), and esophageal adenocarcinoma (mean, 2.4) when compared with normal esophagus (mean, 3.9; P = .002).
  • Manganese superoxide dismutase expression was similar for esophageal adenocarcinoma and high-grade dysplasia.
  • CONCLUSIONS: Manganese superoxide dismutase expression is significantly reduced in patients with BE with high-grade dysplasia and esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Esophageal Neoplasms / metabolism. Precancerous Conditions / metabolism. Superoxide Dismutase / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365243.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


35. Li Y, Wo JM, Ray MB, Jones W, Su RR, Ellis S, Martin RC: Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma. World J Gastroenterol; 2006 Feb 14;12(6):928-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
  • RESULTS: The expressions of both COX-2 and EGFR increased along with the progression from BE to esophagus adenocarcinoma (EAC).
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Cyclooxygenase 2 / genetics. Esophageal Neoplasms / etiology. Gene Expression Regulation / physiology. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1995 Nov 3;83(3):473-82 [8521477.001]
  • [Cites] Science. 1995 Jul 14;269(5221):234-8 [7618085.001]
  • [Cites] Oncogene. 1996 Feb 15;12(4):893-901 [8632912.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Biochem Pharmacol. 1996 Jul 26;52(2):237-45 [8694848.001]
  • [Cites] Cancer Causes Control. 1996 May;7(3):322-7 [8734825.001]
  • [Cites] Am J Gastroenterol. 1997 Jan;92(1):37-41 [8995934.001]
  • [Cites] Semin Surg Oncol. 1997 Jul-Aug;13(4):270-80 [9229415.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):198-204 [9892207.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Acta Gastroenterol Belg. 2000 Jan-Mar;63(1):13-7 [10907313.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8 [11597398.001]
  • [Cites] Int J Cancer. 2001 Nov 20;95(6):343-9 [11668514.001]
  • [Cites] Ann N Y Acad Sci. 2001 Apr;928:327-35 [11795524.001]
  • [Cites] Adv Exp Med Biol. 2002;507:403-7 [12664617.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1566-72 [12684433.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11 [15179620.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5930-9 [15355926.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Cell. 1990 Apr 20;61(2):203-12 [2158859.001]
  • [Cites] J Endocrinol. 1990 Jun;125(3):339-43 [2197365.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1146-53 [1659742.001]
  • [Cites] Ann Intern Med. 1992 Sep 1;117(5):408-14 [1503333.001]
  • [Cites] Cancer Res. 1992 Oct 15;52(20):5575-89 [1394181.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25934-8 [1464605.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Am J Gastroenterol. 1993 Mar;88(3):402-8 [8438848.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Arch Biochem Biophys. 1993 Oct;306(1):169-77 [8215400.001]
  • [Cites] Ann N Y Acad Sci. 1993 Nov 30;696:197-204 [7509130.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3228-32 [8159730.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Science. 1995 Jul 14;269(5221):230-4 [7618084.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • (PMID = 16521222.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC4066159
  •  go-up   go-down


36. Melstrom LG, Bentrem DJ, Salvino MJ, Blum MG, Talamonti MS, Printen KJ: Adenocarcinoma of the gastroesophageal junction after bariatric surgery. Am J Surg; 2008 Jul;196(1):135-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the gastroesophageal junction after bariatric surgery.
  • METHODS: A retrospective review was conducted to identify patients who had undergone bariatric surgery (1999 to 2006) and who later developed high-grade dysplasia or adenocarcinoma of the distal esophagus.
  • CONCLUSIONS: Our findings emphasize the importance of precise endoscopic evaluation before bariatric surgery in patients with gastroesophageal reflux disease (GERD), of the necessity for continuing postsurgical surveillance in patients with known Barrett's esophagitis, and of early evaluation in patients who develop new symptoms of GERD after bariatric surgery.
  • [MeSH-major] Adenocarcinoma / etiology. Bariatric Surgery. Esophageal Neoplasms / etiology. Esophagogastric Junction. Postoperative Complications
  • [MeSH-minor] Aged. Barrett Esophagus / etiology. Gastroesophageal Reflux / etiology. Humans. Male. Middle Aged. Obesity, Morbid / complications. Obesity, Morbid / surgery. Retrospective Studies


37. Muldoon TJ, Anandasabapathy S, Maru D, Richards-Kortum R: High-resolution imaging in Barrett's esophagus: a novel, low-cost endoscopic microscope. Gastrointest Endosc; 2008 Oct;68(4):737-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution imaging in Barrett's esophagus: a novel, low-cost endoscopic microscope.
  • BACKGROUND: This report describes the clinical evaluation of a novel, low-cost, high-resolution endoscopic microscope for obtaining fluorescent images of the cellular morphology of the epithelium of regions of the esophagus with Barrett's metaplasia.
  • PATIENTS, INTERVENTIONS, AND MAIN OUTCOME MEASUREMENTS: The tissue samples studied in this report were obtained by endoscopic resection from patients with previous diagnoses of either high-grade dysplasia or esophageal adenocarcinoma.
  • RESULTS: Three distinct tissue types were observed ex vivo with the endoscopic microscope: normal squamous mucosa, Barrett's metaplasia, and high-grade dysplasia.
  • Barrett's metaplasia could be identified by large glandular structures with intact nuclear polarity.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4478-82 [16002837.001]
  • [Cites] Eur J Clin Pharmacol. 1999 Apr;55(2):95-100 [10335902.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):979-87 [16843068.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):166-9 [17185100.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):144-9 [17591488.001]
  • [Cites] Dig Dis. 2000-2001;18(4):195-202 [11356990.001]
  • [Cites] Biomed Pharmacother. 2001 Jul;55(6):295-300 [11478579.001]
  • [Cites] Dis Esophagus. 2002;15(2):106-8 [12220415.001]
  • [Cites] Gut. 2003 Jan;52(1):18-23 [12477753.001]
  • [Cites] ANZ J Surg. 2003 Mar;73(3):121-4 [12608973.001]
  • [Cites] Scand J Gastroenterol Suppl. 2003;(237):37-9 [12797680.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):715-9 [14595307.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7870-5 [14633715.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Dig Dis. 2004;22(2):134-41 [15383754.001]
  • [Cites] Arch Intern Med. 1991 Nov;151(11):2212-6 [1953225.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):686-95 [16246680.001]
  • (PMID = 18926182.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB007594-02; United States / NCI NIH HHS / CA / CA103830; United States / NCI NIH HHS / CA / R01 CA103830-05; United States / NIDDK NIH HHS / DK / P30 DK56338; United States / NIBIB NIH HHS / EB / EB007594-02; United States / NIDDK NIH HHS / DK / P30 DK056338; United States / NCI NIH HHS / CA / R01 CA103830; United States / NIBIB NIH HHS / EB / R01 EB007594; United States / NIBIB NIH HHS / EB / R01 EB002179
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ NIHMS187221; NLM/ PMC2869299
  •  go-up   go-down


38. Portale G, Peters JH, Hsieh CC, Hagen JA, DeMeester SR, DeMeester TR: Can clinical and endoscopic findings accurately predict early-stage adenocarcinoma? Surg Endosc; 2006 Feb;20(2):294-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can clinical and endoscopic findings accurately predict early-stage adenocarcinoma?
  • Therefore, we conducted a study to determine whether symptomatic and endoscopic findings can accurately identify node-negative early-stage adenocarcinoma.
  • METHODS: A total of 213 consecutive patients (171 men and 42 women) with resectable esophageal adenocarcinoma seen from 1992 to 2002 were evaluated.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Esophageal Neoplasms / complications. Esophageal Neoplasms / diagnosis. Esophagoscopy
  • [MeSH-minor] Aged. Anemia / etiology. Barrett Esophagus / etiology. Deglutition Disorders / etiology. Female. Gastroesophageal Reflux / etiology. Gastrointestinal Hemorrhage / etiology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pain / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):23-8 [8836712.001]
  • [Cites] Gastrointest Endosc. 1996 Nov;44(5):578-82 [8934165.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2059-64 [10616977.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):433-8; discussion 438-40 [10493489.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Ann Thorac Surg. 1998 Mar;65(3):787-92 [9527214.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):689-96 [11726843.001]
  • [Cites] Gastrointest Endosc. 1999 Jan;49(1):8-12 [9869716.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Gastrointest Endosc. 1995 Jul;42(1):64-70 [7557181.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1156-63 [12190682.001]
  • [Cites] Gastroenterology. 1995 Feb;108(2):337-44 [7835574.001]
  • [Cites] Gut. 2004 May;53(5):634-40 [15082579.001]
  • [Cites] Radiology. 1991 Nov;181(2):419-25 [1924783.001]
  • [Cites] Ann Surg. 2000 May;231(5):635-43 [10767784.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 May;125(5):1091-102 [12771883.001]
  • [Cites] Am J Gastroenterol. 2003 Jul;98(7):1627-33 [12873590.001]
  • (PMID = 16333557.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. von Conrady D, Smith MJ, Khan MF, Tan S, Mortimer G, McAnena OJ: Progression of Barrett's esophagus to adenocarcinoma despite antireflux surgery. Endoscopy; 2008 Sep;40 Suppl 2:E68-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of Barrett's esophagus to adenocarcinoma despite antireflux surgery.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Barrett Esophagus / surgery. Esophageal Neoplasms / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633915.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Räsänen JV, Sihvo EI, Ahotupa MO, Färkkilä MA, Salo JA: The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours. Eur J Surg Oncol; 2007 Dec;33(10):1164-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study we investigated whether DNA damage linked to oxidative stress (as 8-OHdG) is present in Barrett's mucosa with or without associated adenocarcinoma or high-grade dysplasia and in normal controls' squamous mucosa.
  • EXPERIMENTAL DESIGN: We measured 8-OHdG in 51 patients (13 Barrett's metaplasia, six Barrett's oesophagus with high-grade dysplasia, 18 adenocarcinoma of the distal oesophagus/oesophagogastric junction and 14 normal controls).
  • RESULTS: Analysis revealed that 8-OHdG was present in both Barrett's metaplasia with and without dysplasia as well as in adenocarcinoma of the oesophagus/oesophagogastric junction.
  • Although the study group was small the amount of 8-OHdG was significantly increased in the distal oesophagus both in Barrett's epithelium 1.26 (0.08-29.47) and in high-grade dysplasia 1.35 (1.04-1.65) as well as in adenocarcinoma of oesophagus/oesophagogastric junction 1.08 (0.59-1.94) compared to controls 0.06 (0-4.08) (p=0.002, p=0.012, p=0.001, respectively).
  • Barrett's patients had no significant difference in 8-OHdG levels between their distal and proximal oesophageal samples.
  • CONCLUSIONS: Our results show the presence of oxidative DNA damage in the distal oesophagus of patients with Barrett's oesophagus and adenocarcinoma of the oesophagus/oesophagogastric junction.
  • This may have a connection to carcinogenesis in Barrett's oesophagus.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. DNA Damage / physiology. Deoxyguanosine / analogs & derivatives. Esophageal Neoplasms / metabolism. Esophagus / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17467227.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


41. Hu Y, Williams VA, Gellersen O, Jones C, Watson TJ, Peters JH: The pathogenesis of Barrett's esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells. J Gastrointest Surg; 2007 Jul;11(7):827-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathogenesis of Barrett's esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells.
  • INTRODUCTION: Clinical evidence strongly suggests that bile acids are important in the development of Barrett's esophagus, although the mechanism remains unknown.
  • Caudal-related homeobox 2 (CDX2) is a transcription factor recently implicated in early differentiation and maintenance of normal intestinal epithelium and is suggested to play a key role in the pathogenesis of intestinal metaplasia in Barrett's esophagus.
  • (2) adenocarcinoma (SEG-1); and (3) squamous cell carcinoma (HKESC-1 & HKESC-2), were exposed in cell culture for 1-24 h to 100-1,000 microM deoxycholic, chenodeoxycholic, and glycocholic acids.
  • The maximal induction of CDX2 expression was seen in SEG-1 adenocarcinoma cells.
  • Expression in Het-1A cells also increased significantly as did expression in HKESC-1,2 cells, although to a lesser extent than in adenocarcinoma.
  • They further support the role of bile acids in the pathogenesis of Barrett's esophagus and link the clinical evidence of a high prevalence of luminal bile acids in Barrett's to expression of the gene thought to be responsible for the phenotypic expression of intestinal metaplasia.
  • [MeSH-major] Barrett Esophagus / etiology. Bile Acids and Salts / physiology. Esophagus / pathology. Homeodomain Proteins / genetics. Intestines / microbiology. Mucins / genetics. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2008 Aug;143(8):807 [18711046.001]
  • [ErratumIn] J Gastrointest Surg. 2008 Feb;12(2):400 [18071834.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):120-7 [12127396.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1442-7 [14576477.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Apr 15;118(2):112-20 [10748291.001]
  • [Cites] J Gastroenterol. 2003;38(1):14-22 [12560917.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):689-96 [11875002.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):769-74 [12239615.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 7;294(2):470-9 [12051735.001]
  • [Cites] Surgery. 1997 Nov;122(5):874-81 [9369886.001]
  • [Cites] Mod Pathol. 2004 Oct;17 (10 ):1282-8 [15167938.001]
  • [Cites] Surgery. 2005 Nov;138(5):924-31 [16291394.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10 ):1063-8 [15452161.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):595-603 [10027336.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):365-71 [1703038.001]
  • [Cites] Gut. 2006 Jan;55(1):16-25 [16118348.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):619-25 [8552090.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):712-6; discussion 716-7 [15249402.001]
  • (PMID = 17458588.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Duplicate Publication; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 0 / RNA, Messenger
  •  go-up   go-down


42. Eckman MH, Ying J, Hertzfeld K, Kumar N, Barrett W: Longitudinal analysis of genitourinary and bowel symptoms in prostate cancer patients following brachytherapy. Am J Clin Oncol; 2010 Feb;33(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Multiple options with similar cure rates exist for men with localized adenocarcinoma of the prostate.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Aged. Comorbidity. Constipation / etiology. Diarrhea / etiology. Erectile Dysfunction / etiology. Humans. Iodine Radioisotopes / adverse effects. Longitudinal Studies. Male. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636237.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23 DK075599; United States / NHLBI NIH HHS / HL / K30 HL078581-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


43. Bisschops R, Bergman J: Probe-based confocal laser endomicroscopy: scientific toy or clinical tool? Endoscopy; 2010 Jun;42(6):487-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Microscopy, Confocal

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Endoscopy. 2010 Jun;42(6):435-40 [20506064.001]
  • (PMID = 20506066.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Germany
  •  go-up   go-down


44. Kountouras J, Chatzopoulos D, Zavos C: Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus. Med Hypotheses; 2007;68(5):1174-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus.
  • [MeSH-major] Adenocarcinoma / microbiology. Barrett Esophagus / microbiology. Esophageal Neoplasms / microbiology. Gastroesophageal Reflux / microbiology. Helicobacter pylori. Models, Biological

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196756.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Gastrins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / bcl-Associated Death Protein; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


45. Keswani RN, Noffsinger A, Waxman I, Bissonnette M: Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev; 2006 Jul;15(7):1243-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical use of p53 in Barrett's esophagus.
  • Barrett's esophagus is an established precursor to esophageal adenocarcinoma.
  • Whereas most patients with Barrett's esophagus do not progress to adenocarcinoma, patients with progression have a poor prognosis.
  • Furthermore, given the relatively high prevalence of Barrett's esophagus but low incidence of progression, this invasive and expensive approach has not been shown to be cost-effective.
  • Thus, there is intense interest in using biomarkers to identify patients at increased risk of progressing to adenocarcinoma.
  • In this report, we discuss the biology of p53 and the incidence of p53 mutations in Barrett's esophagus and review relevant studies regarding the ability of p53 to predict neoplastic progression.
  • Continuing efforts, therefore, are needed to define and prospectively validate a panel of biomarkers to risk-stratify patients with Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835318.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 69
  •  go-up   go-down


46. Leers JM, DeMeester SR, Ayazi S, Tang AL, Peyre CG, Lipham JC, Hagen JA, DeMeester TR: Recurrence of intramucosal esophageal adenocarcinoma arising in a former esophagostomy site: a unique case report. Dis Esophagus; 2009;22(6):E17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intramucosal esophageal adenocarcinoma arising in a former esophagostomy site: a unique case report.
  • A 75-year-old male with a long history of gastroesophageal reflux symptoms developed adenocarcinoma proximally within a long segment of Barrett's esophagus.
  • Pathology showed an intramucosal adenocarcinoma, limited to the muscularis mucosa with surrounding high-grade dysplasia and intestinal metaplasia.
  • The proximal esophageal margin showed no tumor cells, but there was low-grade dysplasia within Barrett's esophagus.
  • Biopsy revealed an implant metastasis of esophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021685.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Patti MG, Waxman I: Gastroesophageal reflux disease: From heartburn to cancer. World J Gastroenterol; 2010 Aug 14;16(30):3743-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About 10%-15% of patients with gastroesophageal reflux disease develop Barrett's esophagus.
  • This is considered a premalignant condition because it can progress from metaplasia to high-grade dysplasia, and eventually to adenocarcinoma.
  • Recently, major advances have been made in the endoscopic treatment of Barrett's esophagus, therefore limiting the role of surgery in the treatment of this disease.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / etiology. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / complications. Heartburn / etiology. Precancerous Conditions / etiology

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Heartburn.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2002 May;122(5):1500-11 [11984534.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):274-9 [11943125.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):933 [9314878.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):890-7; discussion 897-8 [15531244.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):189-90 [17329188.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):286-90 [17458599.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1 [18043101.001]
  • [Cites] Gastrointest Endosc. 2008 Jul;68(1):35-40 [18355819.001]
  • [Cites] Eur J Cardiothorac Surg. 2009 Jan;35(1):13-20; discussion 20-1 [18952454.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Ann Surg. 2009 Sep;250(3):472-83 [19730178.001]
  • [Cites] Am J Gastroenterol. 2009 Nov;104(11):2684-92 [19690526.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3745-9 [20698035.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3750-6 [20698036.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3757-61 [20698037.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3762-72 [20698038.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3773-9 [20698039.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3780-5 [20698040.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3786-92 [20698041.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3793-803 [20698042.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3804-10 [20698043.001]
  • [Cites] World J Gastroenterol. 2010 Aug 14;16(30):3811-5 [20698044.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):467-86 [9309398.001]
  • (PMID = 20698034.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial; Introductory Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2921083
  •  go-up   go-down


48. Madisch A, Miehlke S, Bayerdorffer E, Wiedemann B, Antos D, Sievert A, Vieth M, Stolte M, Schulz H: Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation. World J Gastroenterol; 2005 Feb 28;11(8):1182-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation.
  • AIM: To report the long-term outcome of patients after complete ablation of non-neoplastic Barrett's esophagus (BE) with respect to BE relapse and development of intraepithelial neoplasia or esophageal adenocarcinoma.
  • At each surveillance endoscopy four-quadrant biopsies were taken from the neo-squamous epithelium at 2 cm intervals depending on the pre-treatment length of BE mucosa beginning at the neo-Z-line, and from any endoscopically suspicious lesion.
  • In none of the patients, intraepithelial neoplasia nor an esophageal adenocarcinoma was detected.
  • [MeSH-major] Barrett Esophagus / therapy. Laser Coagulation
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Argon. Carcinoma in Situ / epidemiology. Cohort Studies. Esophageal Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754401.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 67XQY1V3KH / Argon
  • [Other-IDs] NLM/ PMC4250710
  •  go-up   go-down


49. Yeh RW, Triadafilopoulos G: Endoscopic therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am; 2005 Jul;15(3):377-97, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic therapy for Barrett's esophagus.
  • With the increase in the rate of esophageal adenocarcinoma in the United States and the Western world matched with the high morbidity and mortality of esophagectomy, there is an increasing need for new and effective techniques to treat and prevent esophageal adenocarcinoma.
  • Most studies show that specialized intestinal metaplasia may persist underneath neo-squamous mucosa, posing a risk for subsequent neoplastic progression.
  • In this article we review current published literature on endoscopic therapies for the management of Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / therapy. Endoscopy, Gastrointestinal

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990048.001).
  • [ISSN] 1052-5157
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


50. Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol; 2005 Sep;36(9):955-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
  • We investigated endoglin and vascular endothelial growth factor (VEGF) expression as possible prognostic markers in esophageal adenocarcinoma.
  • Surgical specimens from 75 patients with esophageal adenocarcinoma treated with esophagectomy were immunostained for endoglin, CD31, and VEGF.
  • We also included 10 cases of Barrett's esophagus with high-grade dysplasia and 10 cases with Barrett's esophagus low-grade dysplasia.
  • Endoglin showed a significant increase in MV count in Barrett's esophagus with high-grade dysplasia when compared with Barrett's esophagus low-grade dysplasia (P < .01), whereas CD31 did not show any significant difference.
  • VEGF was expressed in 48 (64%) of 75 cases of adenocarcinoma and was significantly correlated with angiolymphatic invasion, LN metastases, and survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Esophageal Neoplasms / diagnosis. Vascular Cell Adhesion Molecule-1 / analysis. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Adult. Aged. Antigens, CD. Antigens, CD31 / analysis. Barrett Esophagus / metabolism. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Receptors, Cell Surface

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16153457.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Cell Adhesion Molecule-1; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


51. Hammoud ZT, Dobrolecki L, Kesler KA, Rahmani E, Rieger K, Malkas LH, Hickey RJ: Diagnosis of esophageal adenocarcinoma by serum proteomic pattern. Ann Thorac Surg; 2007 Aug;84(2):384-92; discussion 392
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of esophageal adenocarcinoma by serum proteomic pattern.
  • BACKGROUND: Currently, endoscopic biopsy is the only method used to diagnose esophageal adenocarcinoma.
  • Using surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology, we sought to identify a potentially diagnostic serum protein pattern that can serve as a reliable blood test for the diagnosis of esophageal adenocarcinoma.
  • In addition, we sought to identify potential biomarkers for esophageal adenocarcinoma.
  • METHODS: Whole serum was collected using standard techniques from subjects with a known diagnosis of esophageal adenocarcinoma as well as from subjects without any known esophageal disease.
  • CONCLUSIONS: Serum proteomic pattern shows great promise in the diagnosis of esophageal adenocarcinoma.
  • This technology may lead to the development of a noninvasive screening test as well as to the identification of potential novel biomarkers for esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Blood Proteins / genetics. Esophageal Neoplasms / genetics. Neoplasm Proteins / genetics. Proteome
  • [MeSH-minor] Barrett Esophagus / complications. Biopsy. Decision Trees. Humans. Oligonucleotide Array Sequence Analysis. Prognosis. Reproducibility of Results. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643604.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


52. Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ, Maley CC: A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila); 2010 Nov;3(11):1388-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.
  • We obtained molecular data from a cohort of 239 participants with Barrett's esophagus, including microsatellite shifts and loss of heterozygosity, DNA content tetraploidy and aneuploidy, methylation, and sequence mutations.
  • Using these data, we tested all major diversity measurement methods, including genetic divergence and entropy-based measures, to determine which measures are correlated with risk of progression to esophageal adenocarcinoma.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Nat Rev Cancer. 2010 Feb;10(2):87-101 [20094044.001]
  • [Cites] Cancer Biomark. 2009;5(3):143-58 [19407369.001]
  • [Cites] J Clin Invest. 2010 Feb;120(2):636-44 [20101094.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1702-10 [10815888.001]
  • [Cites] Science. 2001 Oct 26;294(5543):843-5 [11679667.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] J Pathol. 2003 Mar;199(3):354-60 [12579537.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] J Oral Pathol Med. 2004 Jul;33(6):317-22 [15200478.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1198-210 [1936790.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):210-2 [7550353.001]
  • [Cites] Nat Med. 1996 Jun;2(6):682-5 [8640560.001]
  • [Cites] Oncogene. 1997 May 1;14(17):2059-70 [9160886.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 18;89(12):857-62 [9196251.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] Oncogene. 1999 Feb 4;18(5):1185-96 [10022124.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):924-35 [17109012.001]
  • [Cites] Ecology. 2006 Dec;87(12):3186-99 [17249242.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Mol Diagn Ther. 2007;11(5):277-90 [17963416.001]
  • [Cites] Cell Oncol. 2007;29(6):507-17 [18032827.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):354-60 [18202409.001]
  • [Cites] Vet Microbiol. 2008 Apr 1;128(1-2):126-35 [18022331.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [CommentIn] Cancer Prev Res (Phila). 2010 Nov;3(11):1361-4 [20959519.001]
  • (PMID = 20947487.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA132450; United States / NCI NIH HHS / CA / P30 CA010815; United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / R01 CA107028; United States / NCI NIH HHS / CA / R03 CA137811; United States / NCI NIH HHS / CA / R01 CA14065; United States / NCI NIH HHS / CA / P01 CA91955; United States / NCI NIH HHS / CA / R01 CA140657; United States / NCI NIH HHS / CA / R01 CA119224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS225369; NLM/ PMC3004782
  •  go-up   go-down


53. Barritt AS 4th, Shaheen NJ: Should patients with Barrett's oesophagus be kept under surveillance? The case against. Best Pract Res Clin Gastroenterol; 2008;22(4):741-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should patients with Barrett's oesophagus be kept under surveillance? The case against.
  • Barrett's oesophagus, or columnar metaplasia of the oesophagus, is a known risk factor for adenocarcinoma of the oesophagus.
  • Barrett's oesophagus is thought to be the result of longstanding gastro-oesophageal reflux disease, a very common diagnosis in the United States and other western countries.
  • Because Barrett's oesophagus is a transition state between a common complaint and a devastating illness, endoscopic screening and surveillance strategies are commonly employed.
  • However, neither screening nor surveillance strategies have been proven to reduce mortality from oesophageal adenocarcinoma.
  • We address the multifaceted case against surveillance for oesophageal adenocarcinoma.
  • The overall incidence of oesophageal adenocarcinoma is very low, especially compared to other cancers where surveillance is used.
  • The pace of progression from Barrett's to adenocarcinoma is not known.
  • There are drawbacks to endoscopic surveillance for dysplasia and adenocarcinoma in patients with established Barrett's oesophagus that include sampling error, inconsistent pathologic interpretation of biopsies, and cost.
  • Taken individually or together, these limitations make a strong case against surveillance endoscopy in Barrett's oesophagus.
  • [MeSH-major] Barrett Esophagus / diagnosis. Endoscopy, Gastrointestinal / contraindications. Mass Screening / methods. Population Surveillance / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Best Pract Res Clin Gastroenterol. 2008;22(4):721-39 [18656826.001]
  • (PMID = 18656827.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


54. Pondugula K, Wani S, Sharma P: Barrett's esophagus and esophageal adenocarcinoma in adults: long-term GERD or something else? Curr Gastroenterol Rep; 2007 Dec;9(6):468-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus and esophageal adenocarcinoma in adults: long-term GERD or something else?
  • Esophageal adenocarcinoma (EAC) is a highly lethal tumor and is currently the most rapidly rising incidence cancer in the Western world.
  • Numerous risk factors in the development of Barrett's esophagus (BE) (a precursor of EAC) and EAC itself have been identified and are likely multifactorial.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / etiology. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / complications

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2005-12 [11467625.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Nov 15;22(10):1005-10 [16268976.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):34-41; quiz 311 [17631128.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2160-6 [17019737.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):148-52 [11391635.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2693-703 [17227516.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):918-22 [2394347.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):757-60 [10919748.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):2-8 [10566604.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):306-9 [11588545.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Am J Gastroenterol. 2006 Nov;101(11):2619-28 [16952280.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1554-66 [15887151.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Am J Epidemiol. 2005 Sep 1;162(5):454-60 [16076833.001]
  • [Cites] Am J Clin Nutr. 2001 Nov;74(5):631-6 [11684531.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):365-9 [11535879.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Carcinogenesis. 2003 Dec;24(12):1951-60 [12970071.001]
  • [Cites] Surgery. 1994 Feb;115(2):176-81 [8310406.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Gut. 2005 Nov;54(11):1527-35 [16227357.001]
  • [Cites] J Natl Cancer Inst. 2003 May 21;95(10):750-7 [12759393.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1328-31 [12094845.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1754-61 [16030113.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2087-102 [17498505.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1668-73 [16985029.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1293-7 [9260792.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gut. 2002 Sep;51(3):323-8 [12171951.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):582-5 [9128303.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2481-6 [16284367.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):50-7 [9649458.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10 ):2151-6 [16181362.001]
  • [Cites] Am J Gastroenterol. 2003 Jul;98(7):1627-33 [12873590.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1449-56 [9352846.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2323-30; quiz 2331 [17581269.001]
  • [Cites] Am J Gastroenterol. 2003 Aug;98(8):1719-24 [12907324.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1421-9 [16863542.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] Ann Intern Med. 2000 Aug 1;133(3):165-75 [10906830.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 18377797.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] H6241UJ22B / Selenium
  • [Number-of-references] 67
  •  go-up   go-down


55. El-Serag HB, Naik AD: Surveillance in Barrett's esophagus: lessons from behavioral economics. Gastroenterology; 2009 Sep;137(3):763-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance in Barrett's esophagus: lessons from behavioral economics.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Patient Educ Couns. 2005 Jun;57(3):294-9 [15893211.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):429-36 [16083700.001]
  • [Cites] Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv [16545207.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):694-702 [17416759.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):588-99 [18272361.001]
  • [Cites] JAMA. 2007 Nov 28;298(20):2415-7 [18042920.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):842-9 [18076733.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Sep 15;28(6):789-98 [19145734.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):519-25 [19114703.001]
  • [Cites] N Engl J Med. 2007 Sep 27;357(13):1340-4 [17898105.001]
  • (PMID = 19643189.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / K23 AG027144; United States / NIA NIH HHS / AG / AG027144-03; United States / NIA NIH HHS / AG / K23 AG027144-03; United States / NIDDK NIH HHS / DK / K24DK078154-03; United States / NIDDK NIH HHS / DK / K24 DK078154; United States / NIA NIH HHS / AG / 5K23AG027144; United States / NIDDK NIH HHS / DK / DK078154-03; United States / NIDDK NIH HHS / DK / K24 DK078154-03
  • [Publication-type] Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS181765; NLM/ PMC2855541
  •  go-up   go-down


56. Lee OJ, Schneider-Stock R, McChesney PA, Kuester D, Roessner A, Vieth M, Moskaluk CA, El-Rifai W: Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia; 2005 Sep;7(9):854-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.
  • Chronic gastroesophageal reflux disease is a known risk factor for Barrett's esophagus (BE), which induces oxidative mucosal damage.
  • In this study, we have investigated the mRNA and protein expression of GPx3, and explored promoter hypermethylation as an epigenetic mechanism for GPx3 gene inactivation during Barrett's carcinogenesis.
  • Quantitative real-time reverse transcription polymerase chain reaction on 42 Barrett's adenocarcinomas (BAs) revealed consistently reduced levels of GPx3 mRNA in 91% of tumor samples.
  • GPx3 promoter hypermethylation was detected in 62% of Barrett's metaplasia, 82% of dysplasia, and 88% of BA samples.
  • Immunohistochemical staining of GPx3 in matching tissue sections (normal, BE, Barrett's dysplasia, and BA) revealed strong immunostaining for GPx3 in normal esophageal and gastric tissues.
  • However, weak to absent GPx3 staining was observed in Barrett's dysplasia and adenocarcinoma samples where the promoter was hypermethylated.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 1999 Nov;27(9-10):951-65 [10569628.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Dis Esophagus. 2000;13(1):28-31 [11005328.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:189-200 [11506813.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):47-95 [11773609.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):26-33 [11781277.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):55-9 [11781280.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):22-6 [11808965.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41254-8 [12185074.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1688-97 [12721243.001]
  • [Cites] FASEB J. 2003 Jul;17(10):1195-214 [12832285.001]
  • [Cites] Ann Intern Med. 1978 Jul;89(1):122-7 [208444.001]
  • [Cites] Science. 1985 Jan 25;227(4685):375-81 [2981433.001]
  • [Cites] Arch Biochem Biophys. 1987 Aug 1;256(2):677-86 [3619451.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Arch Biochem Biophys. 1991 May 1;286(2):330-6 [1897960.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Sep;9(9):881-5 [9355787.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2265-70 [9395230.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):G1463-71 [9843785.001]
  • [Cites] Nutr Cancer. 1998;32(2):64-70 [9919613.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):81-5 [10076569.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Arch Biochem Biophys. 1993 Sep;305(2):541-5 [8373192.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29382-4 [7961915.001]
  • [Cites] Gut. 1995 Aug;37(2):168-73 [7557561.001]
  • [Cites] Am J Surg. 1995 Dec;170(6):552-6; discussion 556-7 [7491999.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2557-63 [8637913.001]
  • [Cites] Eur J Cancer. 1996 Jan;32A(1):30-8 [8695238.001]
  • [Cites] Dis Esophagus. 1997 Jan;10(1):29-32; discussion 33 [9079270.001]
  • [Cites] Exp Physiol. 1997 Mar;82(2):291-5 [9129943.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2619-22 [9205067.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • (PMID = 16229808.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.11.1.- / GPX3 protein, human; EC 1.11.1.9 / Glutathione Peroxidase
  • [Other-IDs] NLM/ PMC1501938
  •  go-up   go-down


57. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, Swanson SJ, Godfrey TE, Litle VR: MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg; 2008 Feb;135(2):255-60; discussion 260
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of our study was to examine microRNA expression in Barrett esophagus and esophageal cancer to identify potential markers for disease progression.
  • METHODS: MicroRNA was isolated from 35 frozen specimens (10 adenocarcinoma, 10 squamous cell carcinoma, 9 normal epithelium, 5 Barrett esophagus, and 1 high-grade dysplasia).
  • The third branch contained 4 Barrett esophagus samples and 1 squamous cell carcinoma sample.
  • The fourth contained all the adenocarcinoma samples and 1 sample each of Barrett esophagus, normal epithelium, squamous cell carcinoma, and high-grade dysplasia.
  • Supervised classification with principal component analysis determined that the normal epithelium samples were more similar to the squamous cell carcinoma tumors, whereas the Barrett esophagus samples were more similar to adenocarcinoma.
  • Prediction analysis of microarray classified 3 Barrett esophagus samples as Barrett esophagus, 1 as adenocarcinoma, and 1 as normal epithelium.
  • MicroRNA expression may prove useful for identifying patients with Barrett esophagus at high risk for progression to adenocarcinoma.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Sep;230(3):433-8; discussion 438-40 [10493489.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1290-7 [15741182.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2478-85 [15814623.001]
  • [Cites] Surg Clin North Am. 2005 Jun;85(3):621-30 [15927656.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):16-23 [15990814.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Dis Esophagus. 2000;13(1):5-11 [11005324.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1918-24; discussion 1924-5 [11789772.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1982-6 [11960541.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] Dis Esophagus. 2002;15(2):106-8 [12220415.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):486-94; discussion 494-5 [14530720.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1030-4 [12917761.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):439-43 [16437272.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3346-56 [16449976.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Arch Intern Med. 2004 Jul 26;164(14):1482-8 [15277277.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Ann Surg. 1996 Jul;224(1):66-71 [8678620.001]
  • [Cites] Semin Surg Oncol. 1997 Jul-Aug;13(4):270-80 [9229415.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Gastrointest Endosc. 1999 Feb;49(2):170-6 [9925694.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • (PMID = 18242245.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA128057-01; United States / NCI NIH HHS / CA / R03 CA128057; United States / NCI NIH HHS / CA / R03 CA128057-01
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS39623; NLM/ PMC2265073
  •  go-up   go-down


58. Onwuegbusi BA, Rees JR, Lao-Sirieix P, Fitzgerald RC: Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines. PLoS One; 2007 Jan 31;2(1):e177
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.
  • Oesophageal adenocarcinoma arises from Barrett's oesophagus, progresses rapidly and is usually fatal.
  • We therefore investigated the role of TGFbeta in Barrett's associated oesophageal adenocarcinoma using a panel of cell lines (OE33, TE7, SEG, BIC, FLO).
  • 4/5 adenocarcinoma cell lines failed to cell cycle arrest, down-regulate c-Myc or induce p21 in response to TGFbeta, and modulation of a Smad3/4 specific promoter was inhibited.
  • These hyperproliferative adenocarcinoma cell lines displayed a TGFbeta induced increase in the expression of the extracellular matrix degrading proteinases, urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1), which correlated with an invasive cell phenotype as measured by in vitro migration, invasion and cell scattering assays.
  • These results suggest that TGFbeta Smad-dependent signalling is perturbed in Barrett's carcinogenesis, resulting in failure of growth-arrest.
  • These data would support a dual role for TGFbeta in oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Signal Transduction / physiology. Smad3 Protein / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Barrett Esophagus / complications. Cell Cycle / physiology. Cell Line, Tumor. Cell Proliferation. Enzyme Activation. Enzyme Inhibitors / metabolism. Extracellular Matrix / metabolism. Extracellular Signal-Regulated MAP Kinases / genetics. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation. Humans. JNK Mitogen-Activated Protein Kinases / genetics. JNK Mitogen-Activated Protein Kinases / metabolism. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2000 Feb;182(2):269-80 [10623891.001]
  • [Cites] Gut. 2006 Jun;55(6):764-74 [16368780.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):400-8 [11283614.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):172-80 [11505062.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S44-51 [11684442.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3905-14 [11719557.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):237-46 [11786417.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3150-7 [11689575.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):207-10 [12023852.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3749-59 [12110587.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):391-401 [12538493.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5941-6 [12493778.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5978-85 [15184866.001]
  • [Cites] Surgery. 2004 Aug;136(2):310-6 [15300196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2438-42 [2871553.001]
  • [Cites] J Biol Chem. 1991 Jan 15;266(2):1092-100 [1985937.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1583-92 [1923525.001]
  • [Cites] J Biol Chem. 1991 Dec 5;266(34):23048-52 [1744101.001]
  • [Cites] J Biol Chem. 1992 Mar 15;267(8):5029-31 [1544886.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1785-94 [7907940.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7117-24 [7706248.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):23007-12 [7559439.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1152-5 [8869332.001]
  • [Cites] Eur J Biochem. 1996 Oct 15;241(2):393-402 [8917435.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):1-22 [9212216.001]
  • [Cites] Genes Dev. 1997 Dec 1;11(23):3157-67 [9389648.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):135-44 [9422531.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):721-30 [9495240.001]
  • [Cites] Nat Med. 1998 Aug;4(8):923-8 [9701244.001]
  • [Cites] Nature. 1998 Aug 27;394(6696):909-13 [9732876.001]
  • [Cites] Clin Exp Metastasis. 1999 Feb;17(1):77-85 [10390151.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4782-8 [15930298.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):407-15 [10652434.001]
  • (PMID = 17264880.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Smad3 Protein; 0 / Transforming Growth Factor beta; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC1766472
  • [General-notes] NLM/ Original DateCompleted: 20070723
  •  go-up   go-down


59. Spechler SJ, Davila R: Endoscopic therapy in Barrett's esophagus: when and how? Surg Oncol Clin N Am; 2009 Jul;18(3):509-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic therapy in Barrett's esophagus: when and how?
  • Endoscopic ablative therapy, and endoscopic mucosal resection (EMR) are the two general types of endoscopic therapies available for the treatment of Barrett's esophagus.
  • In this article, we discuss the use of endoscopic therapies for Barrett's esophagus presenting with no neoplasia, low and high-grade dysplasia, and early adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / surgery. Catheter Ablation / methods. Esophagoscopy / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / etiology. Adenocarcinoma / surgery. Algorithms. Biopsy. Combined Modality Therapy. Decision Trees. Endosonography. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / etiology. Esophageal Neoplasms / surgery. Esophagectomy / methods. Evidence-Based Practice. Humans. Lymph Node Excision. Neoplasm Staging. Patient Selection. Precancerous Conditions / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / surgery. Proton Pump Inhibitors / therapeutic use. Risk Reduction Behavior. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500740.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  • [Number-of-references] 52
  •  go-up   go-down


60. Chemaly M, Scalone O, Durivage G, Napoleon B, Pujol B, Lefort C, Hervieux V, Scoazec JY, Souquet JC, Ponchon T: Miniprobe EUS in the pretherapeutic assessment of early esophageal neoplasia. Endoscopy; 2008 Jan;40(1):2-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a retrospective study, which summarized our clinical experience with various miniprobe techniques in the assessment of early squamous cell carcinoma (SCC) and superficial adenocarcinoma on Barrett's mucosa (SAB).
  • [MeSH-major] Adenocarcinoma / ultrasonography. Barrett Esophagus / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Endosonography / instrumentation. Esophageal Neoplasms / ultrasonography. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2008 Jan;40(1):71-2 [18210344.001]
  • (PMID = 18058614.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Sayana H, Wani S, Sharma P: Esophageal adenocarcinoma and Barrett's esophagus. Minerva Gastroenterol Dietol; 2007 Jun;53(2):157-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma and Barrett's esophagus.
  • Esophageal adenocarcinoma (EAC) is the most rapidly rising incidence cancer associated with a poor 5-year survival rate.
  • Barrett's esophagus (BE) is a well established premalignant condition for the development of EAC and hence it is imperative that patients with BE or at risk for developing BE should be identified and managed appropriately.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / etiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557044.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 95
  •  go-up   go-down


62. Lagergren J, Viklund P: Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux? World J Surg; 2007 Mar;31(3):465-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux?
  • BACKGROUND: Gastroesophageal reflux is the main risk factor for esophageal adenocarcinoma, but there is no strong support for a protective effect of antireflux surgery.
  • We tested the hypothesis that esophageal adenocarcinoma that develops with long latency after antireflux surgery might be due to persistent postoperative reflux.
  • RESULTS: One hundred and eighty-nine out of 216 (88%) eligible cases of esophageal adenocarcinoma and 820 of 1,128 (73%) controls were prospectively enrolled.
  • All 7 case patients had Barrett's mucosa.
  • CONCLUSIONS: Esophageal adenocarcinoma occurring late after antireflux surgery might at least partly be due to persistent postoperative reflux.
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / surgery
  • [MeSH-minor] Adult. Aged. Anti-Ulcer Agents / therapeutic use. Barrett Esophagus / epidemiology. Barrett Esophagus / etiology. Case-Control Studies. Female. Humans. Interviews as Topic. Male. Middle Aged. Prospective Studies. Registries. Risk Factors. Sweden / epidemiology. Treatment Failure

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2007 Mar;31(3):447-9 [17334863.001]
  • [CommentIn] World J Surg. 2007 Sep;31(9):1900; author reply 1901 [17627326.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] N Engl J Med. 1992 Mar 19;326(12):786-92 [1538721.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):49-54 [15973101.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):458-64; discussion 464-6 [14530718.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):434-41 [15120368.001]
  • [Cites] N Engl J Med. 1980 Apr 10;302(15):844-8 [7360162.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1286-93 [11729107.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):327-35 [10419913.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Am J Surg. 2003 Dec;186(6):652-9 [14672774.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] JAMA. 2001 May 9;285(18):2331-8 [11343480.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):66-72 [12837713.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2390-4 [14638338.001]
  • [Cites] Ann Intern Med. 2000 Aug 1;133(3):165-75 [10906830.001]
  • (PMID = 17171490.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents
  •  go-up   go-down


63. Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk. Future Oncol; 2007 Apr;3(2):127
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / prevention & control. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Barrett Esophagus / drug therapy. Biomarkers, Tumor / blood. Esophageal Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381411.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53; R16CO5Y76E / Aspirin
  •  go-up   go-down


64. Playford RJ: The value of surveillance and other unresolved issues in the management of Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol; 2005 Feb;2(2):60-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of surveillance and other unresolved issues in the management of Barrett's esophagus.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / diagnosis. Barrett Esophagus / therapy. Esophageal Neoplasms / etiology. Esophagoscopy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265103.001).
  • [ISSN] 1743-4378
  • [Journal-full-title] Nature clinical practice. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Clin Pract Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Quaroni L, Casson AG: Characterization of Barrett esophagus and esophageal adenocarcinoma by Fourier-transform infrared microscopy. Analyst; 2009 Jun;134(6):1240-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of Barrett esophagus and esophageal adenocarcinoma by Fourier-transform infrared microscopy.
  • Matched histologically normal esophageal squamous epithelium (NS), premalignant Barrett esophagus (BE), and primary esophageal adenocarcinoma (EADC) tissues, each defined according to strict clinicopathologic criteria, were obtained from patients who underwent esophageal resection.
  • [MeSH-major] Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Spectroscopy, Fourier Transform Infrared / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Cluster Analysis. Goblet Cells / cytology. Goblet Cells / pathology. Humans. Intestines / pathology. Light. Metaplasia / pathology. Microscopy. Synchrotrons

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475154.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Inomata Y, Koike T, Ohara S, Abe Y, Sekine H, Iijima K, Ariizumi K, Yamagishi H, Kitagawa Y, Imatani A, Shimosegawa T: Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status. Am J Gastroenterol; 2006 May;101(5):926-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status.
  • BACKGROUND: We have previously reported that Helicobacter pylori infection prevents reflux esophagitis (RE) and Barrett's esophagus (BE) by decreasing gastric acid secretion.
  • Gastroesophageal (GE) junction adenocarcinoma, including Barrett's adenocarcinoma, has been thought to be a complication of gastroesophageal reflux disease (GERD).
  • However, the relationship between H. pylori infection, gastric acid secretion, and GE junction adenocarcinoma has not yet been investigated in Japan.
  • METHODS: A total of 168 Japanese patients (RE alone: 80, short-segment BE (SSBE): 16, long-segment BE (LSBE): 20, GE junction adenocarcinoma: 12, distal early gastric cancer (EGC): 40; male/female = 106/62; mean age 61.5 yr) and 80 Japanese control subjects who had no localized lesions in the upper gastrointestinal tract (male/female = 43/37, mean age 58.1 yr) were enrolled for this study.
  • On the other hand, while the prevalence of H. pylori infection in patients with GE junction adenocarcinoma (58.3%) was significantly lower than that in patients with EGC (87.5%), it tended to be higher than that in patients with RE alone or BE.
  • The mean EGT value in patients with GE junction adenocarcinoma (3.94) was significantly higher than that in control subjects and patients with EGC (0.67), but it was comparable to that independent of the H. pylori infection status in patients with RE alone or BE.
  • CONCLUSION: Preservation of gastric acid secretion may be important for the development of GE junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / physiopathology. Esophageal Neoplasms / complications. Esophageal Neoplasms / physiopathology. Esophagitis, Peptic / physiopathology. Esophagogastric Junction. Gastric Acid / secretion. Helicobacter Infections / complications. Helicobacter pylori
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / physiopathology. Female. Gastric Acidity Determination. Gastrins / analysis. Humans. Male. Middle Aged. Prevalence. Stomach Neoplasms / complications. Stomach Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2006 May;101(5):934-6 [16696780.001]
  • (PMID = 16573782.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


67. Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, Bronner MP, Taylor SL, Grace MG, Depot M, International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus: Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc; 2005 Oct;62(4):488-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.
  • BACKGROUND: Barrett's esophagus (BE) may lead to high-grade dysplasia (HGD) and adenocarcinoma.
  • The objective was to examine the impact of treating patients with BE and with HGD by using porfimer sodium (POR) and photodynamic therapy (PDT) for ablating HGD and reducing the incidence of esophageal adenocarcinoma.
  • The occurrence of adenocarcinoma in the PORPDT group (13%) (n=18) was significantly lower (p < 0.006) compared with the OM group (28%) [corrected] (n=20).
  • CONCLUSIONS: PORPDT in conjunction with omeprazole is an effective therapy for ablating HGD in patients with BE and in reducing the incidence of esophageal adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / drug therapy. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Precancerous Conditions / drug therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Aged. Biopsy. Disease Progression. Esophageal Neoplasms / pathology. Esophageal Neoplasms / prevention & control. Esophagoscopy. Female. Follow-Up Studies. Humans. International Cooperation. Male. Prospective Studies. Treatment Outcome


68. Pouw RE, Sharma VK, Bergman JJ, Fleischer DE: Radiofrequency ablation for total Barrett's eradication: a description of the endoscopic technique, its clinical results and future prospects. Endoscopy; 2008 Dec;40(12):1033-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for total Barrett's eradication: a description of the endoscopic technique, its clinical results and future prospects.
  • Stepwise circumferential and focal radiofrequency ablation using the HALO system is a novel and promising ablative modality for Barrett's esophagus.
  • Primary circumferential ablation is performed using a balloon-based bipolar electrode, while secondary treatment of residual Barrett's epithelium is performed using an endoscope-mounted bipolar electrode on an articulated platform.
  • Recent studies suggest that this ablation technique is highly effective in removing Barrett's mucosa and its associated dysplasia without the known drawbacks of photodynamic therapy or argon plasma coagulation, such as esophageal stenosis and subsquamous foci of intestinal metaplasia (also known as "buried Barrett").
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Catheter Ablation / instrumentation. Esophageal Neoplasms / surgery. Esophagoscopy / methods. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065488.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 36
  •  go-up   go-down


69. Bobryshev YV, Tran D, Killingsworth MC, Buckland M, Lord RV: Dendritic cells in Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg; 2009 Jan;13(1):44-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cells in Barrett's esophagus and esophageal adenocarcinoma.
  • BACKGROUND: Like other premalignant conditions that develop in the presence of chronic inflammation, the development and progression of Barrett's esophagus is associated with the development of an immune response, but how this immune response is regulated is poorly understood.
  • A comprehensive literature search failed to find any report of the presence of dendritic cells in Barrett's intestinal metaplasia and esophageal adenocarcinoma and this prompted our study.
  • MATERIAL AND METHODS: We used immunohistochemical staining and electron microscopy to examine whether dendritic cells are present in Barrett's esophagus and esophageal adenocarcinoma.
  • Immunohistochemical staining with CD83, a specific marker for dendritic cells, was performed on paraffin-embedded sections of Barrett's intestinal metaplasia (IM, n = 12), dysplasia (n = 11) and adenocarcinoma (n = 14).
  • RESULTS: CD83+ cells were identified in the lamina propria surrounding intestinal type glands in Barrett's IM, dysplasia, and cancer tissues.
  • Double immunostaining with CD83, CD20, and CD3, and electron microscopy demonstrated that dendritic cells are present in Barrett's esophagus and form clusters with T cells and B cells directly within the lamina propria.
  • CONCLUSIONS: These findings demonstrate that dendritic cells are present in Barrett's tissues, with a significant increase in density in adenocarcinoma compared to benign Barrett's esophagus.
  • Dendritic cells may have a role in the pathogenesis and immunotherapy treatment of Barrett's esophagus and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Dendritic Cells / ultrastructure. Esophageal Neoplasms / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Immunol Rev. 2004 Jun;199:9-26 [15233723.001]
  • [Cites] Cancer Immunol Immunother. 2004 Nov;53(11):978-86 [15197496.001]
  • [Cites] Int J Cancer. 1996 Sep 27;68(1):1-7 [8895531.001]
  • [Cites] Cancer Immunol Immunother. 2007 Dec;56(12):1967-77 [17564704.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Pathology. 1996 Nov;28(4):321-7 [9007950.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):473-83 [11506482.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Immunol Cell Biol. 2002 Dec;80(6):520-30 [12406385.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):1047-60 [10071300.001]
  • [Cites] Am J Clin Pathol. 1994 Jun;101(6):761-7 [8209866.001]
  • [Cites] Cardiovasc Res. 1998 Mar;37(3):799-810 [9659465.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):10-21 [17618050.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1813-21 [11748282.001]
  • [Cites] Immunol Rev. 2007 Dec;220:151-68 [17979845.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Apr;13(4):356-62 [9641297.001]
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):585-93 [9533525.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2136-47 [11391595.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(5):351-5 [8322450.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1755-66 [10815894.001]
  • [Cites] Arch Histol Cytol. 1995 Aug;58(3):307-22 [8527238.001]
  • [Cites] Int Immunopharmacol. 2003 Aug;3(8):1061-71 [12860163.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):534-40 [2455589.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;61(6):409-14 [1349780.001]
  • [Cites] Pathol Res Pract. 1991 May;187(4):496-502 [1876530.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):483-90 [9815709.001]
  • [Cites] Tohoku J Exp Med. 1993 Mar;169(3):187-95 [8248911.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):97-130 [11773610.001]
  • [Cites] Annu Rev Immunol. 2003;21:685-711 [12615891.001]
  • [Cites] J Exp Med. 1973 May 1;137(5):1142-62 [4573839.001]
  • [Cites] J Leukoc Biol. 1993 Jan;53(1):19-28 [8426088.001]
  • [Cites] Int Arch Allergy Immunol. 2002 Oct;129(2):113-8 [12403928.001]
  • [Cites] Int J Oncol. 1994 Aug;5(2):231-6 [21559580.001]
  • [Cites] Adv Cancer Res. 2002;84:231-76 [11883529.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):496-503 [2912528.001]
  • [Cites] Immunobiology. 2002 Jul;205(3):231-46 [12182451.001]
  • [Cites] Am J Gastroenterol. 2006 Jun;101(6):1178-82 [16771933.001]
  • [Cites] Eur J Immunol. 2007 Mar;37(3):634-48 [17266176.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] Nat Rev Immunol. 2004 Dec;4(12):941-52 [15573129.001]
  • [Cites] J Pathol. 2005 Nov;207(3):269-76 [16177953.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):419-26 [17898760.001]
  • [Cites] Cell. 2002 Mar 22;108(6):755-67 [11955430.001]
  • [Cites] Dig Dis Sci. 2008 Jul;53(7):1739-46 [18080193.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360.001]
  • [Cites] Springer Semin Immunopathol. 2005 Jan;26(3):289-307 [15609003.001]
  • [Cites] Immunol Invest. 2000 May;29(2):177-85 [10854187.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):103-8 [10974412.001]
  • [Cites] Cell Oncol. 2007;29(6):507-17 [18032827.001]
  • [Cites] Cancer Invest. 2004;22(3):417-34 [15493363.001]
  • (PMID = 18685901.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD83 antigen; 0 / Immunoglobulins; 0 / Membrane Glycoproteins
  •  go-up   go-down


70. Ochs-Balcom HM, Falk G, Grady WM, Kinnard M, Willis J, Elston R, Eng C, Chak A: Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma. Transl Res; 2007 Jul;150(1):3-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma.
  • The Familial Barrett's Esophagus Consortium began in 1998 and was originally designed to investigate the evidence for familial aggregation of Barrett's esophagus, esophageal adenocarcinoma, or esophagogastric junctional adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585859.001).
  • [ISSN] 1931-5244
  • [Journal-full-title] Translational research : the journal of laboratory and clinical medicine
  • [ISO-abbreviation] Transl Res
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA30722; United States / PHS HHS / / CAD43703; United States / NIDDK NIH HHS / DK / DK002800; United States / NIDDK NIH HHS / DK / DK061426; United States / NIDDK NIH HHS / DK / DK070863; United States / NIGMS NIH HHS / GM / GM28356; United States / NCI NIH HHS / CA / R25 CA094186
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


71. Falk GW: Risk factors for esophageal cancer development. Surg Oncol Clin N Am; 2009 Jul;18(3):469-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of esophageal adenocarcinoma is increasing at a rate greater than that of any other cancer in the Western world today.
  • Barrett's esophagus is a clearly recognized risk factor for the development of esophageal adenocarcinoma, but the overwhelming majority of patients with Barrett's esophagus will never develop esophageal cancer.
  • To date, dysplasia remains the only factor useful for identifying patients at increased risk for the development of esophageal adenocarcinoma in clinical practice.
  • Factors that may protect against the development of adenocarcinoma include infection with Helicobacter pylori, a diet rich in fruits and vegetables, and consumption of aspirin and NSAIDs.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500737.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 125
  •  go-up   go-down


72. Turcotte S, Duranceau A: Gastroesophageal reflux and cancer. Thorac Surg Clin; 2005 Aug;15(3):341-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The causal relationship between GERD and esophageal adenocarcinoma, although unclear just a few decades ago, now is established fairly well.
  • The physiologic changes and the biocellular alterations of the damaged esophageal mucosa are documented better.
  • The absolute risk of esophageal adenocarcinoma arising from GERD is low, and, at present, does not justify population-screening programs.
  • Still, with the notion that adenocarcinoma of the esophagus is an aggressive cancer once documented, important questions still are in need of answers for patients suffering from reflux symptoms.
  • Once documented, Barrett's esophagus needs to be seen as a premalignant condition not necessarily leading to adenocarcinoma formation; despite their increased risk of tumor formation, most patients who have Barrett's esophagus die of other causes.
  • It still is unclear if medicine or surgery provides the best quality of life and the best protection against the development of dysplasia and the possible progression toward adenocarcinoma formation when intestinal metaplasia is present in the esophagus.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Gastroesophageal Reflux / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104125.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


73. Andreu Garcia M: [Esophageal adenoma-carcinoma and Barrett's esophagus. Gastric adenocarcinoma and Helicobacter pylori]. Gastroenterol Hepatol; 2008 Oct;31 Suppl 4:66-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Esophageal adenoma-carcinoma and Barrett's esophagus. Gastric adenocarcinoma and Helicobacter pylori].
  • [Transliterated title] Adenocarcinoma esfágico y esófago de Barrett. Adenocarcinoma gástrico y Helicobacter pylori.
  • In the meeting of the American Gastroenterological Association, notable among all the studies presented on the prevention and treatment of esophageal and gastric cancer were the following contributions: the use of clinical practice guidelines for the prevention and surveillance of Barrett's esophagus (BE) should be improved; treatment with proton pump inhibitors does not seem to reduce the risk of esophageal cancer; endoscopic therapy of intramucosal cancer through complete mucosal resection is effective; Helicobacter pylori eradication prevents the development of metachronous gastric cancer in patients treated for a first intramucosal adenocarcinoma through endoscopic resection; the risk of developing gastric cancer is 6 times higher in patients with mucosa-associated lymphoid tissue (MALT) lymphoma than in the general population; and photodynamic therapy may be an alternative for the treatment of "invisible" gastric adenocarcinoma, which should be followed-up endoscopically.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / etiology


74. Van Den Eynde M, Jouret-Mourin A, Sempoux C, Piessevaux H, Deprez PH: Endoscopic mucosal or submucosal resection of early neoplasia in Barrett's esophagus after antireflux surgery. Gastrointest Endosc; 2010 Oct;72(4):855-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal or submucosal resection of early neoplasia in Barrett's esophagus after antireflux surgery.
  • BACKGROUND: Endoscopic resection and radiofrequency ablation are now established therapies for high-grade intraepithelial neoplasia and mucosal cancer complicating Barrett's esophagus.
  • OBJECTIVE: To assess the results of endoscopic resection for early neoplasia complicating Barrett's esophagus after antireflux surgery.
  • PATIENTS: This study involved 7 patients treated for Barrett's neoplasia by endoscopic resection between 2001 and 2009.
  • Pathology examination disclosed invasive adenocarcinoma in 3 patients and high-grade intraepithelial neoplasia in 4 patients.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / complications. Carcinoma in Situ / surgery. Esophageal Neoplasms / surgery. Fundoplication. Gastroesophageal Reflux / surgery

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20883865.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Michalak J, Bansal A, Sharma P: Screening and surveillance of Barrett's esophagus. Curr Gastroenterol Rep; 2009 Jun;11(3):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and surveillance of Barrett's esophagus.
  • Esophageal adenocarcinoma (EAC) is the most rapidly increasing cancer in the Western world and Barrett's esophagus (BE) is the only known precursor lesion for this lethal cancer.
  • [MeSH-major] Barrett Esophagus. Endoscopy, Gastrointestinal / methods. Mass Screening / methods. Population Surveillance / methods

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2005 Aug;39(7):572-8 [16000923.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):979-87 [16843068.001]
  • [Cites] Virchows Arch. 2003 Jan;442(1):18-24 [12536310.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2693-703 [17227516.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Transl Res. 2007 Jul;150(1):3-17 [17585859.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):24-31 [18442484.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 [18801365.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):546-54 [17970838.001]
  • [Cites] Dig Dis Sci. 2002 Sep;47(9):2108-11 [12353864.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 1;23(5):595-9 [16480398.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):581-7 [17611911.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1029-38 [17021130.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):945-9 [7926484.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):306-9 [11588545.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Oct;16(10):1795-800 [12269973.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] J Clin Gastroenterol. 1986 Dec;8(6):613-8 [3805655.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):1-10 [15645398.001]
  • [Cites] Histopathology. 2007 Jun;50(7):920-7 [17543082.001]
  • [Cites] J Pathol. 2000 Feb;190(2):177-83 [10657016.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1692-9 [15188164.001]
  • [Cites] Mod Pathol. 2004 Oct;17 (10 ):1282-8 [15167938.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):167-75 [16860063.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):661-70 [14595298.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):849-55 [18547567.001]
  • [Cites] Dig Dis Sci. 1992 Jan;37(1):137-43 [1728519.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):525-32 [17459025.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):534-5 [12958113.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Endoscopy. 2005 Oct;37(10):929-36 [16189764.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):2101-3 [16344076.001]
  • [Cites] J Clin Epidemiol. 2004 Jun;57(6):580-9 [15246126.001]
  • [Cites] Gastroenterology. 2004 Oct;127(4):1233-8 [15481000.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):394-8 [18045592.001]
  • [Cites] Am J Gastroenterol. 2003 Jul;98(7):1627-33 [12873590.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):741-6 [15855985.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):2-9 [17185192.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Gut. 2008 Feb;57(2):167-72 [17965067.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):619-26 [11685024.001]
  • [Cites] Endoscopy. 2007 Jun;39(6):492-6 [17554642.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):188-92 [16860066.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):671-5 [17055854.001]
  • (PMID = 19463219.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


76. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL: Central adiposity and risk of Barrett's esophagus. Gastroenterology; 2007 Aug;133(2):403-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central adiposity and risk of Barrett's esophagus.
  • BACKGROUND AND AIMS: Aside from chronic reflux, the etiology of Barrett's esophagus (BE) remains largely unknown.
  • CONCLUSIONS: These observations indicate the importance of identifying the mechanisms underlying obesity's role in BE and esophageal adenocarcinoma, and suggest that weight loss might be a fruitful approach to the prevention of these diseases.
  • [MeSH-major] Abdominal Fat / physiopathology. Adiposity. Barrett Esophagus / etiology. Esophagus / pathology. Obesity / complications

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681161.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / R01 CA72866
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


77. Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, Manner H, Guenter E, Huijsmans J, Vieth M, Stolte M, Ell C: Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut; 2008 Sep;57(9):1200-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus.
  • OBJECTIVE: Endoscopic therapy is increasingly being used in the treatment of high-grade intraepithelial neoplasia (HGIN) and mucosal adenocarcinoma (BC) in patients with Barrett's oesophagus.
  • PATIENTS: Between October 1996 and September 2002, 61 patients with HGIN and 288 with BC were included (173 with short-segment and 176 with long-segment Barrett's oesophagus) from a total of 486 patients presenting with Barrett's neoplasia.
  • The risk factors most frequently associated with recurrence were piecemeal resection, long-segment Barrett's oesophagus, no ablative therapy of Barrett's oesophagus after CR, time until CR achieved >10 months and multifocal neoplasia.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma in Situ / surgery. Esophageal Neoplasms / surgery. Precancerous Conditions / surgery


78. Siewert JR, Feith M: Adenocarcinoma of the esophagogastric junction: competition between Barrett and gastric cancer. J Am Coll Surg; 2007 Oct;205(4 Suppl):S49-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: competition between Barrett and gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916519.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Brundler MA, Harrison JA, de Saussure B, de Perrot M, Pepper MS: Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma. J Clin Pathol; 2006 Feb;59(2):191-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma.
  • BACKGROUND: Oesophageal adenocarcinoma is an aggressive neoplasm with poor prognosis as a result of early lymph node metastasis.
  • AIMS: To measure lymphatic vessel density (LVD) in the neoplastic progression from Barrett's metaplasia to adenocarcinoma and determine whether LVD can predict the risk of cancer.
  • METHODS: LVD and microvascular density (MVD) were assessed after immunohistochemical staining of vessels in Barrett's metaplasia, dysplasia, and adenocarcinoma tissues and were correlated with clinicopathological features.
  • RESULTS: LVD was significantly reduced in adenocarcinoma, being half that seen in normal stomach/oesophagus or metaplasia/dysplasia.
  • MVD was also assessed as a prognostic marker; its increase appeared to be linked more with the development of Barrett's metaplasia than adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Lymphatic Vessels / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2390-4 [14638338.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):753-8 [10414493.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4324-7 [10969769.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):672-82 [11179212.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2971-9 [12089227.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7059-65 [12460927.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):250-6 [12538477.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Feb;125(2):246-53 [12579092.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1920-6 [12702584.001]
  • [Cites] J Clin Gastroenterol. 2003 May-Jun;36(5 Suppl):S6-18; discussion S26-8 [12702960.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97 [12916666.001]
  • [Cites] World J Surg. 2003 Sep;27(9):999-1008; discussion 1006-8 [12917764.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8555-6; author reply 8558 [14679026.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):358-64 [14746853.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):11-24 [15215158.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1224-5 [15316566.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):755-61 [1377162.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):223-9 [1285217.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2474-84 [9059336.001]
  • [Cites] Ann Intern Med. 1999 Jan 5;130(1):67-9 [9890855.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):789-801 [10037799.001]
  • [Cites] J Pathol. 2000 Sep;192(1):14-8 [10951394.001]
  • (PMID = 16443737.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860317
  •  go-up   go-down


80. Chen MJ, Lee YC, Chiu HM, Wu MS, Wang HP, Lin JT: Time trends of endoscopic and pathological diagnoses related to gastroesophageal reflux disease in a Chinese population: eight years single institution experience. Dis Esophagus; 2010 Apr;23(3):201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discrepancy between Eastern and Western countries exists regarding the time trends of Barrett's esophagus (BE)/adenocarcinoma.
  • BE-associated dysplasia and adenocarcinoma were rare.
  • The incidence of BE-associated dysplasia and adenocarcinoma has been the same and the increased screening did not detect more cancers.


81. Ong CA, Lao-Sirieix P, Fitzgerald RC: Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol; 2010 Dec 07;16(45):5669-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.
  • Barrett's esophagus is a well-known premalignant lesion of the lower esophagus that is characterized by intestinal metaplasia of the squamous epithelium.
  • It is clinically important due to the increased risk (0.5% per annum) of progression to esophageal adenocarcinoma (EA), which has a poor outcome unless diagnosed early.
  • The current clinical management of Barrett's esophagus is hampered by the lack of accurate predictors of progression.
  • Biomarkers have the potential to improve radically the clinical management of patients with Barrett's esophagus and EA but have not yet entered mainstream clinical practice.
  • This review aims to highlight the most promising predictive and prognostic biomarkers in Barrett's esophagus and EA and to discuss what is required to move the field forward towards clinical application.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers, Tumor / analysis. Esophageal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Clin Pathol. 2005 Aug 12;5:7 [16095543.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Cancer Invest. 2001;19(5):554-68 [11458821.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] BMJ. 2009;338:b604 [19336487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] Methods Inf Med. 2001 Mar;40(1):1-5 [11310153.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Dis Esophagus. 2004;17(2):136-40 [15230726.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5021-8 [16707423.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1030-4 [9067264.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):58-65 [18820669.001]
  • [Cites] Lancet. 2003 Nov 1;362(9394):1439-44 [14602436.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2738-41 [15102678.001]
  • [Cites] BMJ. 2009;338:b375 [19237405.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):387-91 [16106245.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):912-9 [17289885.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Genome Res. 1999 May;9(5):482-91 [10330128.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 1;30(7):e28 [11917034.001]
  • [Cites] Surg Endosc. 2010 May;24(5):1144-50 [19997751.001]
  • [Cites] BMC Cancer. 2008;8:254 [18778486.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1118-26 [11350874.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3789-98 [16785472.001]
  • [Cites] Nat Rev Genet. 2010 Mar;11(3):191-203 [20125086.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3459-70 [18825457.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] BMJ. 2009;338:b606 [19502216.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):748-54 [16401681.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):351-8 [15688381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9523-7 [1946366.001]
  • [Cites] Am J Gastroenterol. 2010 Jul;105(7):1523-30 [20461069.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):614-21 [8566611.001]
  • [Cites] Dis Esophagus. 2008;21(2):97-102 [18269642.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Lab Invest. 2007 May;87(5):466-72 [17310216.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gastroenterology. 2010 Dec;139(6):1995-2004.e15 [20621683.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):488-92 [15705458.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2153-60 [19584833.001]
  • [Cites] BMC Cancer. 2006;6:134 [16712734.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 1;23(5):587-93 [16480397.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):264-8 [16477636.001]
  • [Cites] Mol Pathol. 2003 Dec;56(6):313-7 [14645692.001]
  • [Cites] Genome Res. 2006 Aug;16(8):1046-55 [16809668.001]
  • [Cites] Scand J Gastroenterol. 2007 Nov;42(11):1271-4 [17852872.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Dis Esophagus. 2003;16(1):17-23 [12581249.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1755-63 [9676852.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3602-9 [17896157.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4112-5 [19435894.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2284-9 [9122186.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):865-70 [10732760.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] BMJ. 2009;338:b605 [19477892.001]
  • [Cites] Mol Carcinog. 2006 Oct;45(10):786-94 [16921482.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):588-99 [18272361.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2579-83 [15330218.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1887-94 [15447746.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Scand J Gastroenterol. 2007 Jun;42(6):682-8 [17505989.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):330-7 [20028767.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):1933-7 [10928129.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Am J Med. 2010 May;123(5):462-7 [20399324.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8279-87 [19088045.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6192-200 [19789312.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):853-62 [16007088.001]
  • [Cites] Cancer. 2008 May 15;112(10):2173-80 [18348304.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):977-91 [17122988.001]
  • [Cites] Nat Rev Cancer. 2010 Feb;10(2):87-101 [20094044.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Am J Gastroenterol. 2009 May;104(5):1093-6 [19417749.001]
  • [Cites] Drug Discov Today. 2005 Jul 15;10(14):965-76 [16023055.001]
  • [Cites] Ann Thorac Surg. 2001 Sep;72(3):859-66 [11565671.001]
  • [Cites] Am J Gastroenterol. 2009 Oct;104(10):2588-94 [19623166.001]
  • [Cites] N Engl J Med. 1976 Aug 26;295(9):476-80 [940579.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Cancer Metastasis Rev. 2009 Dec;28(3-4):317-26 [19997771.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Am J Gastroenterol. 2009 Feb;104(2):502-13 [19174812.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):955-61 [16153457.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • (PMID = 21128316.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2997982
  •  go-up   go-down


82. Lanas A, Alcedo González J: [Chemoprevention in adenocarcinoma of the esophagus]. Acta Gastroenterol Latinoam; 2007 Mar;37(1):37-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoprevention in adenocarcinoma of the esophagus].
  • [Transliterated title] Quimioprevención en adenocarcinoma de esófago.
  • The incidence of the adenocarcinoma of the esophagus (ACE) has dramatically for the last decades in western countries, which has been associated with a parallel increase in the incidence and prevalence of symptoms associated with gastroesophageal reflux diseases (GERD) and Barrett's esophagus (BE).
  • [MeSH-major] Adenocarcinoma / prevention & control. Barrett Esophagus / drug therapy. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486744.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Number-of-references] 93
  •  go-up   go-down


83. Shaheen NJ: Should we worry about the length of Barrett's esophagus? Gastrointest Endosc; 2005 Nov;62(5):682-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should we worry about the length of Barrett's esophagus?
  • [MeSH-major] Barrett Esophagus / pathology. Esophageal Neoplasms / etiology. Esophagus / pathology
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Humans. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gastrointest Endosc. 2005 Nov;62(5):675-81 [16246678.001]
  • (PMID = 16246679.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23DK59311-01
  • [Publication-type] Comment; Editorial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


84. Thomas T, Singh R, Ragunath K: Trimodal imaging-assisted endoscopic mucosal resection of early Barrett's neoplasia. Surg Endosc; 2009 Jul;23(7):1609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodal imaging-assisted endoscopic mucosal resection of early Barrett's neoplasia.
  • BACKGROUND: Chromoendoscopy is traditionally used to identify inconspicuous Barrett's neoplasia and mark the boundaries before endoscopic mucosal resection (EMR).
  • Trimodal imaging endoscopy is useful in identifying early neoplasia in Barrett's esophagus.
  • The purpose of this study was to determine the efficacy (lateral and deep margin clearance) of trimodal imaging endoscopy-assisted EMR in early Barrett's neoplasia in a tertiary referral setting.
  • METHODS: The entire Barrett's segment was visualized by high-resolution endoscopy followed by autofluorescence imaging, and suspicious areas were identified.
  • RESULTS: Sixteen patients were included: 13 patients had high-grade intraepithelial neoplasia (HGIN); 3 patients had intramucosal carcinoma (IMC); (8 males, median age, 69.5 (range, 50-77) years with Barrett's esophagus (interquartile range (IQR), 2-5 cm; median length, 3 cm).
  • Overall EMR was complete in 14 of 16 (81.2%) patients with early Barrett's neoplasia.
  • Four of 16 patients (18%; all with pre-EMR HGIN) were considered to have incomplete EMR (deep margins involved), but operative histology showed only Barrett's metaplasia in 2 (histological false positive) and IMC in 1.
  • CONCLUSIONS: Trimodal imaging endoscopy is a feasible alternative to chromoendoscopy to identify inconspicuous neoplasia and assist EMR of early neoplasia in Barrett's esophagus.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / pathology. Carcinoma in Situ / surgery. Esophageal Neoplasms / surgery. Esophagoscopy / methods. Fluorometry / methods. Video-Assisted Surgery / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1449-57 [16863545.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):328-32 [10968845.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):167-75 [12872081.001]
  • [Cites] Endoscopy. 2005 Jun;37(6):570-8 [15933932.001]
  • [Cites] Gastrointest Endosc. 1994 Mar-Apr;40(2 Pt 1):224-6 [8013827.001]
  • [Cites] Lancet. 2003 Aug 2;362(9381):373-4 [12907012.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):210-7 [16299789.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):3-10 [17185072.001]
  • [Cites] Endoscopy. 2008 May;40(5):370-9 [18494132.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):47-52 [11154488.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Aug 1;26(3):501-7 [17635385.001]
  • [Cites] Gut. 2008 Feb;57(2):167-72 [17965067.001]
  • [Cites] Gastrointest Endosc. 2001 Mar;53(3):333-5 [11231393.001]
  • (PMID = 19296171.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


85. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV: Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol; 2005 Jun;100(6):1257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
  • BACKGROUND: The incidence of esophageal adenocarcinoma has increased significantly in the western world over the last 20 yr.
  • Most cases arise in a background of chronic gastroesophageal reflux, and specialized intestinal metaplasia in Barrett's esophagus is frequently an antecedent phenotype or evident in association with adenocarcinoma.
  • The molecular events that characterize the pathway from inflammation to metaplasia to dysplasia and adenocarcinoma are poorly understood.
  • AIMS: To examine the expression of the proinflammatory cytokines IL-8 and IL-1beta along the esophagitis, metaplasia, dysplasia, and adenocarcinoma pathway, and to correlate this with histological changes and expression of the transcription factor NF-kappaB.
  • PATIENTS AND METHODS: Fresh biopsy specimens were collected from patients with reflux esophagitis (n=15), Barrett's esophagus (n=35), Barrett's adjacent to adenocarcinoma (n=8), and esophageal adenocarcinoma (n=35).
  • RESULTS: Elevated expression of NF-kappaB was found in 2 (13%) out of 15 patients with reflux esophagitis, 21 (60%) out of 35 patients with Barrett's esophagus, and 28 (80%) out of 35 patients with esophageal adenocarcinoma.
  • All 5 patients with Barrett's esophagus and high-grade dysplasia showed elevated expression of NF-kappaB.
  • IL-8 and IL-1beta were significantly increased in esophagitis, Barrett's, and adenocarcinoma compared with squamous epithelium, and in adenocarcinoma compared with all other groups.
  • There was a stepwise increase in the expression of IL-8, IL-1beta, and NF-kappaB from normal through Barrett's epithelium to adenocarcinoma in eight cases of esophageal adenocarcinoma.
  • The levels of both IL-8 and IL-1beta in adenocarcinoma patients correlated with stage of disease.
  • Patients with adenocarcinoma who were NF-kappaB positive had significantly higher levels of both IL-8 (p=0.04) and IL-1beta (p=0.03) compared to adenocarcinoma patients who were NF-kappaB negative.
  • CONCLUSIONS: The proinflammatory cytokines IL-8 and IL-1beta are elevated in esophagitis and Barrett's epithelium, and markedly elevated in adenocarcinoma.
  • NF-kappaB activation is infrequent in esophagitis, but is increased in Barrett's epithelium and adenocarcinoma.
  • The association of NF-kappaB activation with cytokine upregulation was only evident in patients with adenocarcinoma.
  • These patterns may play an important role in Barrett's inflammation and tumourigenesis, and inhibition of the NF-kappaB/proinflammatory cytokine pathway may be an important target for future chemoprevention strategies.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Esophagitis / metabolism. Interleukin-1 / biosynthesis. Interleukin-8 / biosynthesis. NF-kappa B / biosynthesis
  • [MeSH-minor] Barrett Esophagus / metabolism. Barrett Esophagus / pathology. Biomarkers / metabolism. Biopsy. Electrophoresis. Endoscopy, Digestive System. Enzyme-Linked Immunosorbent Assay. Female. Gastroesophageal Reflux / metabolism. Gastroesophageal Reflux / pathology. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Metaplasia / metabolism. Metaplasia / pathology. Middle Aged. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929754.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interleukin-1; 0 / Interleukin-8; 0 / NF-kappa B
  •  go-up   go-down


86. Bonde P, Gao D, Chen L, Duncan M, Miyashita T, Montgomery E, Harmon JW, Wei C: Selective decrease in the DNA base excision repair pathway in squamous cell cancer of the esophagus. J Thorac Cardiovasc Surg; 2007 Jan;133(1):74-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There was significantly more DNA damage in both adenocarcinoma (n = 15) and squamous cell carcinoma (n = 19), as exemplified by positive 8-oxoguanine expression compared with that seen in control animals (P < .05).
  • 8-Oxoguanine glycosylase was several folds upregulated in adenocarcinoma (P < .05), but there was significantly decreased expression in squamous cell carcinoma (P < .01).
  • [MeSH-minor] Adenocarcinoma / genetics. Animals. Apoptosis Inducing Factor / metabolism. Barrett Esophagus / complications. Barrett Esophagus / genetics. Barrett Esophagus / metabolism. Barrett Esophagus / pathology. Carcinogens. Caspase 3 / metabolism. Cell Transformation, Neoplastic. DNA Damage. DNA Glycosylases / metabolism. Esophagitis / complications. Esophagitis / genetics. Esophagitis / pathology. Esophagus / pathology. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / genetics. Gastroesophageal Reflux / pathology. Guanosine / analogs & derivatives. Guanosine / metabolism. Immunohistochemistry. Male. Nitrosamines. Papilloma / complications. Papilloma / genetics. Papilloma / pathology. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198784.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Inducing Factor; 0 / Carcinogens; 0 / Nitrosamines; 12133JR80S / Guanosine; 13256-07-0 / N-amyl-N-methylnitrosamine; 3868-31-3 / 8-hydroxyguanosine; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


87. Quaroni L, Zhao R, Casson AG: Shining light on Barrett's esophagus. Expert Rev Gastroenterol Hepatol; 2009 Dec;3(6):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shining light on Barrett's esophagus.
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / complications. Barrett Esophagus / diagnosis. Esophageal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19929578.001).
  • [ISSN] 1747-4132
  • [Journal-full-title] Expert review of gastroenterology & hepatology
  • [ISO-abbreviation] Expert Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  •  go-up   go-down


88. Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R: TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology; 2010 Jul;57(1):81-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
  • AIMS: Topoisomerase IIalpha (TOPOIIalpha) and HER-2/neu are chromosome 17q genes coamplified in various cancers; no data exist for Barrett's oesophagus (BO) and BO adenocarcinoma (ADC).
  • The aim was to investigate gene amplification and protein overexpression of TopoIIalpha and Her-2/neu in non-dysplastic BO, dysplastic BO, Barrett ADC, and chromosome 17 aneusomy.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antigens, Neoplasm / genetics. Barrett Esophagus / genetics. Barrett Esophagus / pathology. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Genes, erbB-2

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2006;53(5):393-401 [17013533.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):305-11 [17307036.001]
  • [Cites] Mod Pathol. 2007 May;20(5):584-91 [17396141.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):768-72 [16882699.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5115-23 [17785566.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):403-9 [18261624.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Dec;54(4):347-53 [19047975.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3826-33 [19292734.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Anal Cell Pathol. 2000;20(1):25-32 [11007435.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8 [11121461.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):890-2 [11265171.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):179-86 [14499010.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):288-97 [14978790.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):233-7 [14990588.001]
  • [Cites] Neoplasma. 2004;51(3):193-7 [15254672.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):63-70 [1980607.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):195-211 [7795268.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):761-8 [9284825.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1180-8 [9343325.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60 [9747866.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):28-35 [15762277.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • (PMID = 20557373.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2916224
  •  go-up   go-down


89. Barrett C, Rodrigues D, Bradey N, Strachan R: Intracranial metastasis masquerading as acute subdural haematoma. Br J Neurosurg; 2008 Jun;22(3):444-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Hematoma, Subdural, Acute / diagnosis. Prostatic Neoplasms

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568738.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Olbe L: Strong activation of PAR-2 receptors: a common trigger for the development of gastrointestinal adenocarcinomas? Scand J Gastroenterol; 2007 Sep;42(9):1133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori infection is considered to be an important factor in the development of gastric cancer, while duodenogastroesophageal reflux is claimed to be the main cause of development of esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Receptor, PAR-2 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Animals. Barrett Esophagus / etiology. Gastric Acid / chemistry. Gastric Acid / secretion. Gastroesophageal Reflux / complications. Helicobacter Infections / complications. Helicobacter pylori. Humans. Rats. Trypsin / biosynthesis. Trypsin / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710682.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Receptor, PAR-2; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


91. Steevens J, Schouten LJ, Driessen AL, Huysentruyt CJ, Keulemans YC, Goldbohm RA, van den Brandt PA: Toenail selenium status and the risk of Barrett's esophagus: the Netherlands Cohort Study. Cancer Causes Control; 2010 Dec;21(12):2259-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toenail selenium status and the risk of Barrett's esophagus: the Netherlands Cohort Study.
  • OBJECTIVE: To investigate the association between selenium and the risk of Barrett's esophagus (BE), the precursor lesion of esophageal adenocarcinoma.
  • For BE cases that later progressed to high-grade dysplasia or adenocarcinoma, the RR for a selenium level above the median vs. below the median was 0.64 (95% CI 0.24-1.76).
  • [MeSH-major] Barrett Esophagus / etiology. Nails / chemistry. Selenium / analysis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):224-9 [8423627.001]
  • [Cites] Int J Epidemiol. 1990 Sep;19(3):553-8 [2262247.001]
  • [Cites] Am J Clin Nutr. 1993 May;57(5):662-5 [8480683.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7 [8220096.001]
  • [Cites] Eur J Clin Nutr. 1994 Apr;48(4):253-65 [8039485.001]
  • [Cites] Biometrics. 1994 Dec;50(4):1064-72 [7786988.001]
  • [Cites] Epidemiology. 1996 Jul;7(4):384-90 [8793364.001]
  • [Cites] JAMA. 1996 Dec 25;276(24):1957-63 [8971064.001]
  • [Cites] Biometrics. 2004 Dec;60(4):1015-24 [15606422.001]
  • [Cites] Proc Nutr Soc. 2005 Nov;64(4):527-42 [16313696.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):7-27 [17186419.001]
  • [Cites] Scand J Gastroenterol. 2007 Jan;42(1):17-22 [17190757.001]
  • [Cites] Am J Epidemiol. 2007 Apr 15;165(8):955-65 [17272290.001]
  • [Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Clin Chem. 2007 Jun;53(6):1168-70 [17517594.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):394-8 [18045592.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Am J Epidemiol. 2008 Apr 1;167(7):839-46 [18218607.001]
  • [Cites] J Toxicol Sci. 2008 May;33(2):227-35 [18544914.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Gut. 2009 Jan;58(1):5-15 [18664505.001]
  • [Cites] Dig Dis Sci. 2009 Mar;54(3):572-7 [18654849.001]
  • [Cites] Gastroenterology. 2010 May;138(5):1704-13 [20006613.001]
  • [Cites] J Clin Epidemiol. 1999 Dec;52(12):1165-72 [10580779.001]
  • [Cites] Nutr Cancer. 2000;36(1):7-13 [10798210.001]
  • [Cites] Ann Intern Med. 2000 Aug 1;133(3):165-75 [10906830.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1292-7 [12433705.001]
  • [Cites] J Natl Cancer Inst. 2003 May 21;95(10):750-7 [12759393.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] J Clin Epidemiol. 1990;43(3):285-95 [2313318.001]
  • [Cites] Am J Epidemiol. 1990 Jul;132(1):114-22 [2356804.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):107-12 [8467244.001]
  • (PMID = 20936529.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] H6241UJ22B / Selenium
  • [Other-IDs] NLM/ PMC3006659
  •  go-up   go-down


92. Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore GJ, Quesenberry C, Buffler P: Hemochromatosis gene status as a risk factor for Barrett's esophagus. Dig Dis Sci; 2008 Dec;53(12):3095-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemochromatosis gene status as a risk factor for Barrett's esophagus.
  • Conditions causing high iron levels, such as hemochromatosis, are proposed risk factors for esophageal adenocarcinoma.
  • We conducted a case-control study of persons with a new Barrett's esophagus diagnosis (cases), persons with gastroesophageal reflux disease (GERD) (without Barrett's esophagus), and population controls.
  • There was no significant association between Barrett's esophagus and any hemochromatosis gene defect (odds ratio [OR] = 1.32, 95% confidence interval [CI]: 0.95-1.84), a moderate or severe mutation (OR = 1.54, 95% CI: 0.94-2.52), or a severe mutation (C282Y homozygote or C282Y/H63D heterozygote; OR = 0.77, 95% CI: 0.24-2.48) compared with the population controls.
  • We can conclude from our findings that Barrett's esophagus was not associated with hemochromatosis gene defects, although we cannot exclude small effects.

  • Genetic Alliance. consumer health - Hemochromatosis.
  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Hemochromatosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1119-29 [11470739.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3797-9 [12552996.001]
  • [Cites] Int J Food Sci Nutr. 2003 Nov;54(6):485-90 [14522694.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:40-61 [14633776.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1733-41 [14724826.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] J Natl Cancer Inst. 1986 Apr;76(4):605-10 [3007843.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] Am J Clin Nutr. 1989 Nov;50(5 Suppl):1133-8; discussion 1231-5 [2683721.001]
  • [Cites] Hepatology. 1990 Apr;11(4):566-9 [2158479.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1327-35 [2254769.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] Med Clin North Am. 1992 May;76(3):549-66 [1578956.001]
  • [Cites] J Am Diet Assoc. 1992 Jun;92(6):686-93 [1607564.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):160-2 [7829208.001]
  • [Cites] Ann Nutr Metab. 1994;38(4):192-202 [7832579.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):875-9 [8625192.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21167-76 [8702887.001]
  • [Cites] Nutr Cancer. 1997;27(3):298-309 [9101561.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1801-8 [10469627.001]
  • [Cites] Med Care. 2005 Jan;43(1):34-43 [15626932.001]
  • [Cites] Nutr Rev. 2001 May;59(5):140-8 [11396694.001]
  • [Cites] Ann Clin Lab Sci. 2000 Oct;30(4):354-65 [11045759.001]
  • [Cites] Am J Clin Nutr. 2001 Mar;73(3):638-46 [11237943.001]
  • [Cites] Hepatology. 2001 Mar;33(3):647-51 [11230745.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10):1043-6 [16234052.001]
  • [Cites] J Am Coll Nutr. 2006 Feb;25(1):64-9 [16522934.001]
  • [Cites] Gut. 2006 Apr;55(4):554-62 [16174659.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Sep;23(6):507-16 [16849282.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1403-10 [16979952.001]
  • [Cites] Ann Hematol. 2007 Jan;86(1):17-21 [17013646.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):34-41; quiz 311 [17631128.001]
  • [Cites] Genet Test. 2005 Fall;9(3):231-41 [16225403.001]
  • [Cites] Health Serv Res. 2001 Dec;36(6 Pt 2):180-93 [16148968.001]
  • [Cites] Alcohol. 2005 Apr;35(3):243-9 [16054986.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Blood. 2005 Jul 15;106(2):740-5 [15790781.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Dec;14(12):1188-91 [10634155.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • [Cites] Hepatology. 2000 May;31(5):1160-4 [10796893.001]
  • [Cites] Ann Intern Med. 2000 Sep 5;133(5):329-37 [10979877.001]
  • (PMID = 18470614.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK63616; United States / NIDDK NIH HHS / DK / DK063616-05; United States / NIDDK NIH HHS / DK / K08 DK02697; United States / NIDDK NIH HHS / DK / K08 DK002697; United States / NIDDK NIH HHS / DK / R01 DK063616; United States / NIDDK NIH HHS / DK / DK002697-01; United States / NIDDK NIH HHS / DK / R01 DK063616-05; United States / NIDDK NIH HHS / DK / K08 DK002697-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; E1UOL152H7 / Iron
  • [Other-IDs] NLM/ NIHMS99902; NLM/ PMC2670929
  •  go-up   go-down


93. van Baal JW, Krishnadath KK: High throughput techniques for characterizing the expression profile of Barrett's esophagus. Dis Esophagus; 2008;21(7):634-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High throughput techniques for characterizing the expression profile of Barrett's esophagus.
  • Barrett's esophagus (BE) is the metaplastic change of the normal lined squamous epithelium of the distal esophagus to a columnar type of epithelium as a result of chronic long-standing gastroesophageal reflux disease.
  • Patients with BE have a significantly increased risk of developing an esophageal adenocarcinoma, with an estimated annual incidence varying from 0.4 to 1.8%.
  • Over the last 3 decades, the incidence of BE and its associated adenocarcinoma has increased in Western countries at a rate that exceeds that of any other malignancy.
  • With the upcoming modern high throughput technologies, important progression has been made in unraveling the expression profiles and gaining more insight in the biology of BE and esophageal adenocarcinoma.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564162.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


94. Rucker-Schmidt RL, Sanchez CA, Blount PL, Ayub K, Li X, Rabinovitch PS, Reid BJ, Odze RD: Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol; 2009 Jun;33(6):886-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study.
  • Rarely, dysplasia in Barrett's esophagus (BE) is composed of crypts lined by cuboidal-shaped cells that contain a centrally located nucleus, markedly increased nuclear/cytoplasmic ratio, but without nuclear stratification characteristic of conventional "adenomatous" dysplasia.
  • Eighteen patients with NAD identified over a 6 year period, in a cohort of 270 consecutive patients with BE and without esophageal adenocarcinoma (EA) at baseline, were evaluated for clinical and pathologic features, including association with conventional adenomatous dysplasia and EA, DNA content flow cytometric abnormalities (tetraploidy and aneuploidy) and outcome, over a mean follow-up period of 4.1 years.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):65-74 [18755496.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Am J Clin Pathol. 1978 Jul;70(1):1-5 [696666.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):332-7 [2070985.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1029-38 [17021130.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):524-33 [18300795.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • (PMID = 19194279.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA091955-02; United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / P01 CA091955-02; United States / NCI NIH HHS / CA / P01 CA91955
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS110013; NLM/ PMC2702161
  •  go-up   go-down


95. van Blankenstein M: Cancer of the oesophagus, from bad to worse. J Gastrointestin Liver Dis; 2007 Sep;16(3):293-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology
  • [MeSH-minor] Barrett Esophagus / epidemiology. Cardia. Europe / epidemiology. Humans. Incidence. India / epidemiology. Risk Factors. Smoking / adverse effects. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Gastrointestin Liver Dis. 2007 Sep;16(3):245-9 [17925916.001]
  • (PMID = 17925924.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Romania
  •  go-up   go-down


96. Kuwano H, Sohda M, Kato H, Miyazaki T, Kimura H: [Clinical outline of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outline of Barrett's esophagus].
  • Barrett's esophagus is one of the important gastrointestinal disease in Europe and the United States.
  • It was recognized as not only complication of reflux esophagitis, but also pre-malignant lesion of adenocarcinoma.
  • Recently, realization of Barrett's esophagus is attentioned in Japan, because increasing of reflux esophagitis for westernization of eating habit, living habit and aging of the population.
  • In this section, we present general consideration and clinical research of Barrett's esophagus.
  • We expect Barrett's esophagus will gradually increase near the future and need to research abundantly about controversial point of Barrett's esophagus.
  • We also think it is important to accumulate intensively the clinical data of Barrett's esophagus patients.
  • [MeSH-major] Barrett Esophagus
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Esophageal Neoplasms / etiology. Esophageal Neoplasms / pathology. Esophagus / pathology. Genes, Tumor Suppressor. Helicobacter Infections. Helicobacter pylori. Humans. Metaplasia. Oncogenes. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101224.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


97. Vissers KJ, Dinjens WN, Riegman PH, Tilanus HW, van Dekken H: Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma. Anticancer Res; 2005 Mar-Apr;25(2A):913-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma.
  • BACKGROUND: Oesophageal (Barrett's) and gastric cardia adenocarcinomas are cancers arising at and around the gastro-oesophageal junction.
  • MATERIALS AND METHODS: We investigated the 7q region with a set of 5 polymorphic markers spanning 7q36.1-q36.3 in 33 Barrett-related carcinomas.
  • RESULTS: Overall, the number of allelic loss was higher in Barrett's cancers than in gastric cardia carcinomas (p=0.04).
  • In Barrett's adenocarcinomas, imbalance varied from 28% to 45% (of informative cases) with the highest prevalence at marker D7S483.
  • CONCLUSION: Marker D7S483 can aid in discriminating oesophageal (Barrett's) and gastric cardia carcinomas.
  • Further, this region possibly harbours cancer gene(s) involved in Barrett-related adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Allelic Imbalance. Barrett Esophagus / genetics. Cardia / pathology. Chromosomes, Human, Pair 7 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868927.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


98. Greenawalt DM, Duong C, Smyth GK, Ciavarella ML, Thompson NJ, Tiang T, Murray WK, Thomas RJ, Phillips WA: Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer; 2007 May 1;120(9):1914-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma.
  • To obtain insight into the molecular processes underlying tumorigenesis of the esophagus, we have used cDNA microarrays to compare the gene expression profiles of 128 tissue samples representing the major histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma (ADC)) as well as Barrett's esophagus (BE), the precursor lesion to ADC, and normal esophageal epithelium.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic


99. Wang RH: [New developments for endoscopic management of Barrett's esophagus with high grade dysplasia]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Sep;39(5):534-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New developments for endoscopic management of Barrett's esophagus with high grade dysplasia].
  • Barrett's esophagus is now clearly recognized as a preneoplasic condition.
  • Progression of metaplasia through dysplasia to adenocarcinoma is a widely accepted theory for esophageal carcinogenesis.
  • That high grade dysplasia is frequently found in association with esophageal adenocarcinoma.
  • Long-term endoscopic surveillance of high grade dysplasia in Barrett's esophagus facilitates detection and treatment of esophageal cancers in the early stage.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / therapy. Esophagoscopy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20936731.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


100. Mandal RV, Forcione DG, Brugge WR, Nishioka NS, Mino-Kenudson M, Lauwers GY: Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia. Am J Surg Pathol; 2009 Apr;33(4):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia.
  • Endoscopic mucosal resection (EMR) is being advocated as a diagnostic, staging, and therapeutic technique for the management of Barrett esophagus (BE)-related neoplasia.
  • In this study, we sought to determine morphologic factors, which may influence EUS staging in 35 cases with intramucosal adenocarcinoma diagnosed by subsequent EMR, focusing on tumor characteristics and structural changes associated with BE.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Esophagoscopy / methods. Mucous Membrane / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047893.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement